1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Parkinsonian Disorders in 531 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neuroinflammation is thought to be one of the major pathological mechanisms responsible for Parkinson's disease (PD), and has been a primary target in the development of treatment for PD." | 5.38 | Acacetin protects dopaminergic cells against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuroinflammation in vitro and in vivo. ( Ha, SK; Ju, MS; Kim, HG; Kim, SY; Lee, H; Oh, MS, 2012) |
| "We propose that the appearance of dystonia after 3NP intoxication following dopaminergic striatal denervation is the key symptom predictive of the loss of dopaminergic response." | 5.31 | Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys. ( Bioulac, B; Fernagut, PO; Ghorayeb, I; Stefanova, N; Tison, F; Wenning, GK, 2002) |
| " Then, in mouse models, we assessed whether dextran sodium sulfate-mediated colitis could exert lingering effects on dopaminergic pathways in the brain and whether colitis increased vulnerability to a subsequent exposure to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 4.02 | Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology. ( Caudle, WM; Chang, J; Houser, MC; Joers, V; Kannarkat, GT; Kelly, SD; Keshavarzian, A; Oliver, D; Shannon, KM; Tansey, MG; Yang, Y, 2021) |
| "We demonstrate that Eupatilin alleviates behavioral impairment and dopaminergic neuron loss induced by MPTP through inhibition of neuroinflammation and apoptosis." | 3.96 | Eupatilin prevents behavioral deficits and dopaminergic neuron degeneration in a Parkinson's disease mouse model. ( Li, J; Qin, L; Wang, C; Xie, J; Zhang, Y, 2020) |
| "The PD mouse model was established with the injection of MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and the human neuroblastoma cell line, SH-SY5Y, was administrated with MPP+." | 3.81 | MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting α-synuclein expression in MPTP-induced Parkinson's disease mouse. ( Duan, YL; Li, GF; Wang, ZH; Zhang, JL; Zhang, QS; Zheng, DL, 2015) |
| "To investigate the role of the basal ganglia in parkinsonian tremor, we recorded hand tremor and simultaneous activity of several neurons in the external and internal segments of the globus pallidus (GPe and GPi) in two vervet monkeys, before and after systemic treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and development of parkinsonism with tremor of 5 and 11 Hz." | 3.70 | Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism. ( Bergman, H; Raz, A; Vaadia, E, 2000) |
| " During long-term levodopa therapy, patients develop abnormal movements, dyskinesias, the pathophysiological basis of which is poorly understood." | 3.70 | Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. ( Desimone, R; Fiorani, M; Oldfield, EH; Papa, SM, 1999) |
| "The classical animal models of Parkinson's disease (PD) rely on the use of neurotoxins, including 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine and, more recently, the agricultural chemicals paraquat and rotenone, to deplete dopamine (DA)." | 2.46 | alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach. ( Bazzu, G; Calia, G; Debetto, P; Desole, MS; Grigoletto, J; Miele, E; Migheli, R; Puggioni, G; Rocchitta, G; Serra, PA; Spissu, Y; Zusso, M, 2010) |
| "Parkinson's disease is a neurodegenerative disorder of unknown pathogenesis." | 2.42 | Nitric oxide and reactive oxygen species in Parkinson's disease. ( Ischiropoulos, H; Przedborski, S; Tieu, K, 2003) |
| "Recent genetic studies in familial Parkinson's disease and parkinsonism show several gene mutations." | 2.41 | The parkinsonian models: invertebrates to mammals. ( Akaike, A; Kitamura, Y; Shimohama, S; Taniguchi, T, 2000) |
| "Apomorphine has a far more broad neuroprotective activity in the various models as compared with 1-selegiline and may therefore be an ideal drug to study neuroprotection in parkinsonian subjects with the use of PET or SPECT." | 2.41 | Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. ( Gassen, M; Gross, A; Grünblatt, E; Mandel, S; Youdim, MB, 2000) |
| "Although MPTP produces a parkinsonian syndrome after its conversion to 1-methyl-4-phenylpyridine (MPP+) by type B monoamine oxidase (MAO) in the brain, the etiology of this disease remains obscure." | 2.41 | Environmental estrogen-like chemicals and hydroxyl radicals induced by MPTP in the striatum: a review. ( Obata, T, 2002) |
| "Parkinsonism was induced by injections of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.91 | Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model. ( Huang, CW; Ker, MD; Lin, HC; Wu, YH, 2023) |
| "Our primate model of parkinsonism recapitulates important pathologic features in nature PD and provides an unbiased view of the axis of neuronal vulnerability and resistance." | 1.91 | A primate nigrostriatal atlas of neuronal vulnerability and resilience in a model of Parkinson's disease. ( Hao, ZZ; Huang, M; Li, Y; Liu, R; Liu, S; Liu, X; Sang, X; Shao, M; Shen, Y; Tang, L; Xu, C; Xu, N; Yi, W; Yue, F, 2023) |
| "We first confirmed that synucleinopathies existed in the stomachs of chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/probenecid (MPTP/p)-induced PD mice, as indicated by the significant increase in abnormal aggregated and nitrated α-synuclein in the TH-positive neurons and enteric glial cells (EGCs) of the gastric myenteric plexus." | 1.72 | Gastric Enteric Glial Cells: A New Contributor to the Synucleinopathies in the MPTP-Induced Parkinsonism Mouse. ( Chen, NH; Heng, Y; Li, YY; Wen, L; Yan, JQ; Yuan, YH, 2022) |
| "Atractylon treatment increased the eGFP expression in dose-dependent manner in piggyBac-TANGO assay, decreased cAMP production, and enhanced the levels of p-CREB and BDNF in DRD2 highly expresseding SY-SY5Y cells." | 1.72 | Atractylon, a novel dopamine 2 receptor agonist, ameliorates Parkinsonian like motor dysfunctions in MPTP-induced mice. ( Fan, S; Feng, Y; Huang, C; Jiang, X; Li, F; Li, H; Liu, C; Wang, F; Wu, X; Zhang, Y; Zhou, Z, 2022) |
| "Silibinin administration restored these mitochondrial disorders, as expected for the protection against MPTP injury." | 1.62 | Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson's Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus. ( Fu, J; Fujisaki, H; Hattori, S; Hayashi, T; Ikejima, T; Liu, W; Liu, X; Mizuno, K; Song, S; Wang, C, 2021) |
| "The aetiology of PD psychosis is multifactorial and likely arises from the complex interaction between dopamine replacement therapy and disease state." | 1.62 | Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset. ( Gourdon, JC; Huot, P; Kwan, C; Nuara, SG, 2021) |
| "A moving tremor was also observed by visual inspection during this period." | 1.56 | Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious precl ( Ando, K; Hikishima, K; Inoue, R; Inoue, T; Kawai, K; Komaki, Y; Nishime, C; Nishinaka, E; Okano, H; Urano, K, 2020) |
| "Moclobemide significantly reversed parkinsonism (by 39%, P < 0." | 1.56 | Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset. ( Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG, 2020) |
| "This reduction of parkinsonism was not accompanied by an exacerbation of dyskinesia or PLBs." | 1.56 | Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset. ( Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG, 2020) |
| "Cordycepin treatment alleviated these MPTP-induced changes." | 1.51 | Cordycepin mitigates MPTP-induced Parkinson's disease through inhibiting TLR/NF-κB signaling pathway. ( Cheng, C; Zhu, X, 2019) |
| "Nefazodone is an anti-depressant that interacts with a wealth of pharmacological targets, including some that may exert anti-dyskinetic and anti-psychotic effects in Parkinson's disease (PD), notably serotonin 1A and 2A receptors." | 1.48 | Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset. ( Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG, 2018) |
| "Tanshinone I could also inhibit LPS-induced NF-κB activation in microglia." | 1.42 | Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease. ( Chai, L; Guo, H; Hu, L; Jing, H; Liu, Z; Wang, S; Yang, H, 2015) |
| "Chronic Parkinsonism was induced in the PD group using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and probenecid (MPTP/p)." | 1.42 | Apoptotic Mediators are Upregulated in the Skeletal Muscle of Chronic/Progressive Mouse Model of Parkinson's Disease. ( Erekat, NS, 2015) |
| "Levodopa treatment increased the specific binding of NMDA receptors in the basal ganglia." | 1.42 | Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy. ( Di Paolo, T; Grégoire, L; Jourdain, VA; Morin, N; Morissette, M, 2015) |
| "Gaucher disease is an autosomal recessive disease, caused by a lack or functional deficiency of the lysosomal enzyme, glucocerebrosidase (GCase)." | 1.42 | Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease. ( Alvarez-Fischer, D; Andreas, H; Hirsch, EC; Höglinger, GU; Höllerhage, M; Lu, L; Noelker, C; Oertel, WH; Roscher, R; Sturn, A; Vulinovic, F, 2015) |
| " Chronic administration of vinpocetine (for 14 days) significantly and dose dependently attenuated movement disabilities and oxidative-nitrosative stress in MPTP-treated rats." | 1.42 | Vinpocetine attenuates MPTP-induced motor deficit and biochemical abnormalities in Wistar rats. ( Deshmukh, R; Sharma, S, 2015) |
| "In this model, motor parkinsonism correlates well with the loss of nigral dopaminergic cell bodies but only correlates with in vitro measures of nigrostriatal terminal fields when nigral cell loss does not exceed 50%." | 1.40 | In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment. ( Brown, CA; Karimi, M; Loftin, SK; Perlmutter, JS; Tian, L, 2014) |
| " Pioglitazone dosing protected TH-positive neurons, closely matching the number of PPAR-gamma expressing cells in the ipsilateral SNpc." | 1.40 | Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates. ( Emborg, M; Swanson, C, 2014) |
| " Three common dosing regimens of the MPTP-induced mice model of PD were compared on dopaminergic neurotransmission and serotonin levels in various brain regions." | 1.39 | Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease. ( Bodard, S; Chalon, S; Gochard, A; Gulhan, Z; Pain, S; Prunier-Aesch, C, 2013) |
| "Thus, homologous parkinsonism-related metabolic networks are demonstrable in PD patients and in monkeys with experimental parkinsonism." | 1.38 | Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism. ( Doudet, DJ; Eidelberg, D; Ma, Y; Peng, S; Sossi, V; Spetsieris, PG, 2012) |
| " Chronic administration of MPTP/probenecid (MPTP/p) leads to oxidative stress, induction of apoptosis, and loss of dopominergic neurons which results in motor impairments." | 1.38 | Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease. ( Anandhan, A; Essa, MM; Manivasagam, T; Radhiga, T; Rao, S; Tamilselvam, K, 2012) |
| "Neuroinflammation is thought to be one of the major pathological mechanisms responsible for Parkinson's disease (PD), and has been a primary target in the development of treatment for PD." | 1.38 | Acacetin protects dopaminergic cells against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuroinflammation in vitro and in vivo. ( Ha, SK; Ju, MS; Kim, HG; Kim, SY; Lee, H; Oh, MS, 2012) |
| "Treatment with asiaticoside was found to protect dopaminergic neuron by antagonizing MPTP induced neurotoxicity and to improve locomotor dysfunction." | 1.38 | Asiaticoside: attenuation of neurotoxicity induced by MPTP in a rat model of Parkinsonism via maintaining redox balance and up-regulating the ratio of Bcl-2/Bax. ( Deng, JM; Li, LF; Li, XM; Ma, SP; Sun, LM; Wang, QZ; Xu, CL; Xu, R; Zhang, J, 2012) |
| "Levodopa-induced dyskinesias (LIDs) are abnormal involuntary movements induced by the chronic use of levodopa (l-Dopa) limiting the quality of life of Parkinson's disease (PD) patients." | 1.37 | Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias. ( Di Paolo, T; Morissette, M; Parent, M; Riahi, G, 2011) |
| "However, the disease progression remains unaffected, because of continuous dopaminergic neuron loss." | 1.37 | Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. ( Cuadrado, A; Fernández-Ruiz, J; Hesse, M; Innamorato, NG; Jazwa, A; Rojo, AI, 2011) |
| "Posttreatment with benzamide also attenuated MPTP neurotoxicity in mice." | 1.36 | Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. ( Araki, T; Kato, H; Kuroiwa, H; Tsukada, T; Uchida, H; Yokoyama, H, 2010) |
| "Amiloride was found to protect substantia nigra (SNc) neurons from MPTP-induced degeneration, as determined by attenuated reductions in striatal tyrosine hydroxylase (TH) and dopamine transporter (DAT) immunohistochemistry, as well as smaller declines in striatal DAT radioligand binding and dopamine levels." | 1.35 | Amiloride is neuroprotective in an MPTP model of Parkinson's disease. ( Albinson, K; Arias, RL; Beyer, C; Bowlby, MR; Dunlop, J; Dwyer, JM; Kagan, N; Kubek, K; Lin, Q; Monaghan, M; Sung, ML; Vasylyev, D; Zaleska, MM; Zhang, MY, 2008) |
| "When biperiden was combined with SKF-82958, contraversive circling also was enhanced and ipsiversive circling decreased." | 1.35 | Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions. ( Domino, EF; Ni, L, 2008) |
| "Melatonin treatment significantly attenuated both the L-DOPA and MPTP-induced increases in the levels of striatal 6-OHDA, and protected against striatal DA depletion caused by the neurotoxin." | 1.35 | Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. ( Borah, A; Mohanakumar, KP, 2009) |
| " Furthermore, chronic administration of low doses of the 5-HT(1) agonists in combination was able to prevent development of dyskinesia, and reduce the up-regulation of FosB after daily treatment with l-DOPA in the rat 6-OHDA model." | 1.35 | Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. ( Bezard, E; Björklund, A; Carlsson, T; Carta, M; Di Luca, M; Gardoni, F; Kirik, D; Li, Q; Marcello, E; Muñoz, A; Qin, C, 2008) |
| "SUN N8075 is a novel antioxidant with neuroprotective properties." | 1.35 | Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease. ( Adachi, T; Hara, H; Izuta, H; Matsunaga, N; Oida, Y; Oyagi, A; Shimazawa, M, 2008) |
| "Coenzyme Q10 (CoQ10) is a promising agent for neuroprotection in neurodegenerative diseases." | 1.35 | Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. ( Beal, MF; Calingasan, NY; Cleren, C; Lorenzo, B; Schomer, A; Sireci, A; Wille, EJ; Yang, L, 2008) |
| " The data described in the present study provides further evidence that functional deficits following an acute MPTP dosing schedule in mice can be quantified and are related to nigro-striatal dopamine function." | 1.34 | A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl. ( Brackenborough, KT; Chapman, H; Pangalos, MN; Perren, MJ; Quinn, LP; Upton, N; Vidgeon-Hart, M; Virley, DJ; Woodhams, PL, 2007) |
| "Nicotine pretreatment reduced peak and total levodopa-induced dyskinesias in levodopa-naive monkeys over an 8-week period, with a decrease in total dyskinesias of about 50%." | 1.34 | Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. ( Cox, H; Di Monte, D; Langston, JW; O'Leary, K; Parameswaran, N; Quik, M, 2007) |
| "Three monkeys were induced hemiparkinsonism by intracarotid (left) infusion of MPTP (0." | 1.34 | Changes in the rates of the tricarboxylic acid (TCA) cycle and glutamine synthesis in the monkey brain with hemiparkinsonism induced by intracarotid infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): studies by non-invasive 13C-magnetic reso ( Kanamatsu, T; Nambu, A; Okamoto, K; Otsuki, T; Takada, M; Tokuno, H; Tsukada, Y; Umeda, M; Watanabe, H, 2007) |
| "The onset of Parkinsonism is associated with inhibition of the UP system." | 1.33 | Convergent roles of alpha-synuclein, DA metabolism, and the ubiquitin-proteasome system in nigrostriatal toxicity. ( Bandettini Di Poggio, A; De Blasi, A; Fornai, F; Lazzeri, G; Nicoletti, F; Paparelli, A; Ruggieri, S; Soldani, P, 2006) |
| "In this group, the severity of dyskinesias during the third and fourth weeks of treatment was significantly higher than the group treated with l-Dopa alone." | 1.33 | Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys. ( Bédard, PJ; Di Paolo, T; Grégoire, L; Hadj Tahar, A; Rouillard, C; Samadi, P, 2005) |
| " Here we extended the study and investigated TNF-alpha receptor 1 (-/-) (TNFR1) and TNF-alpha receptor 2 (-/-) (TNFR2) mice using a chronic MPTP dosing regimen (15 mg/kg MPTP on 8 consecutive days)." | 1.33 | Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease. ( Feldon, J; Ferger, B; Leng, A; Mura, A, 2005) |
| "Parkinsonism was induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydroisoquinoline(MPTP), and pretreatment with any of the 1MeTIQ derivatives prevented its induction." | 1.33 | Parkinsonism-preventing activity of 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives in C57BL mouse in vivo. ( Kotake, Y; Ohta, S; Okuda, K, 2006) |
| "(3) Substance P distribution was 'reversed' in dopamine depleted striatum: striosomes, which normally express higher levels of substance P, showed decreased expression, whereas substance P expression was up-regulated in the matrix." | 1.32 | Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. ( Betarbet, R; Greenamyre, JT, 2004) |
| " Chronic administration of low doses of MPTP resulted in animals with stable cognitive deficits without overt parkinsonian motor symptoms." | 1.32 | Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys. ( Kulak, JM; Schneider, JS, 2004) |
| "Long-term treatment of Parkinson's disease with levodopa is compromised by the development of motor complications, including on-off fluctuations and involuntary movements termed dyskinesia." | 1.32 | Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. ( Brotchie, JM; Crossman, AR; Duty, S; Fox, SH; Henry, B, 2003) |
| " We investigated whether minocycline would protect against toxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a toxin that selectively destroys nigrostriatal dopaminergic (DA) neurons and produces a clinical state similar to Parkinson's disease (PD) in rodents and primates." | 1.32 | Minocycline enhances MPTP toxicity to dopaminergic neurons. ( Albers, DS; Beal, MF; Browne, SE; Chirichigno, JW; Gregorio, J; Joh, TH; Lorenzl, S; Shimizu, Y; Shin, DH; Sugama, S; Yang, L, 2003) |
| "Tolcapone treatment enhanced CSF DOPAC concentrations in unlesioned animals (by approximately four times) as well as monkeys rendered parkinsonian after severe nigrostriatal dopaminergic injury caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.32 | Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. ( Di Monte, DA; Langston, JW; Thiffault, C, 2003) |
| "These results support reactive gliosis as a means of striatal compensation for dopamine loss." | 1.32 | Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. ( Beales, M; Dervan, AG; McBean, GJ; Meredith, GE; Meshul, CK; Moore, C; Snyder, AK; Totterdell, S, 2004) |
| " Consistent with previous findings, 17beta-estradiol was found to inhibit MPTP-induced DA depletion under a dosing regimen (repeated daily administration) that mimicked physiological levels of the steroid." | 1.32 | Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. ( Liu, X; Menniti, FS; Ramirez, AD, 2003) |
| "Pretreatment with pargyline attenuated the MPTP-induced clinical signs, MRI and MRS changes, and the histopathological and immunoreactivity alterations." | 1.32 | Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism. ( Hadjiconstantinou, M; Neff, NH; Podell, M; Smith, MA, 2003) |
| "Upon recovery from experimental parkinsonism, however, pallidal GABA(A) receptor binding returns to normal levels while mu-opioid receptor binding reflecting enkephalin release remains elevated." | 1.31 | GABA(A) and mu-opioid receptor binding in the globus pallidus and endopeduncular nucleus of animals symptomatic for and recovered from experimental Parkinsonism. ( Schneider, JS; Schroeder, JA, 2002) |
| " In study 1, the authors examined the effect of V-10,367 (50 mg/kg x 2 per day, by mouth) on neurofilament M (NFM) protein levels and on alpha-spectrin breakdown products (SBDPs) when dosed for 2 days, starting 24 hours after TBI and killed on day 3." | 1.31 | Neuroimmunophilin ligand V-10,367 is neuroprotective after 24-hour delayed administration in a mouse model of diffuse traumatic brain injury. ( Detloff, MR; Dutta, S; Hall, ED; Kupina, NC, 2002) |
| "We propose that the appearance of dystonia after 3NP intoxication following dopaminergic striatal denervation is the key symptom predictive of the loss of dopaminergic response." | 1.31 | Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys. ( Bioulac, B; Fernagut, PO; Ghorayeb, I; Stefanova, N; Tison, F; Wenning, GK, 2002) |
| " The lower dosages of (+/-)-kavain (50 and 100 mg/kg) showed only a nonsignificant attenuation of MPTP-induced dopamine depletion, but a high dosage of (+/-)-kavain (200 mg/kg) significantly antagonized the dopamine depletion to 58." | 1.31 | Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease. ( Ferger, B; Schmidt, N, 2001) |
| "It is thought that Parkinson's disease involves apoptosis, and NGF prevents apoptosis in an in vivo model system." | 1.31 | Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease. ( Chiba, H; Shimoke, K, 2001) |
| "Pramipexole treatment also significantly attenuated the loss of tyrosine hydroxylase immunoreactive neurons (TH-IR) within the substantia nigra pars compacta (SNc) in both young and aged animals." | 1.31 | Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. ( Anderson, DW; Neavin, T; Schneider, JS; Smith, JA, 2001) |
| " Treatment with MPTP significantly reduced striatal TH activity, DA and DOPAC, but there were no significant differences in the reductions in any of these parameters observed in the melatonin-treated versus the DMSO-treated control mice that received the same total dosage of MPTP." | 1.31 | Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway. ( Morgan, WW; Nelson, JF, 2001) |
| "We concluded that the TIQ-induced parkinsonism model is different from the MPTP-induced model as evaluated by the radioligand-DATs binding and that (S)-1-MeTIQ has a preventing effect for the degeneration of the DATs to a certain extent." | 1.31 | Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum. ( Abe, K; Ishiwata, K; Kawamura, K; Koyanagi, Y; Saitoh, T; Sano, T; Senda, M; Taguchi, K; Toda, J, 2001) |
| " Mild and advanced parkinsonism in nonhuman primates can be produced with fixed dosing regimens of MPTP." | 1.31 | D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys. ( Goulet, M; Madras, BK, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (1.13) | 18.2507 |
| 2000's | 299 (56.31) | 29.6817 |
| 2010's | 171 (32.20) | 24.3611 |
| 2020's | 55 (10.36) | 2.80 |
| Authors | Studies |
|---|---|
| Nuara, SG | 5 |
| Gourdon, JC | 5 |
| Maddaford, S | 1 |
| Huot, P | 5 |
| Hescham, SA | 1 |
| Chiang, PH | 1 |
| Gregurec, D | 1 |
| Moon, J | 1 |
| Christiansen, MG | 1 |
| Jahanshahi, A | 1 |
| Liu, H | 2 |
| Rosenfeld, D | 1 |
| Pralle, A | 1 |
| Anikeeva, P | 1 |
| Temel, Y | 1 |
| Guo, K | 1 |
| Zhang, Y | 7 |
| Li, L | 5 |
| Zhang, J | 3 |
| Rong, H | 1 |
| Liu, D | 1 |
| Wang, J | 3 |
| Jin, M | 1 |
| Luo, N | 1 |
| Zhang, X | 5 |
| Li, Q | 13 |
| Mo, J | 1 |
| Xiong, B | 1 |
| Liao, Q | 1 |
| Chen, Y | 4 |
| Wang, Y | 5 |
| Xing, S | 1 |
| He, S | 1 |
| Lyu, W | 1 |
| Zhang, N | 1 |
| Sun, H | 2 |
| Li, H | 3 |
| Wang, F | 1 |
| Zhou, Z | 2 |
| Jiang, X | 2 |
| Li, F | 2 |
| Feng, Y | 2 |
| Liu, C | 2 |
| Fan, S | 2 |
| Wu, X | 2 |
| Huang, C | 3 |
| Molinet-Dronda, F | 1 |
| Blesa, J | 2 |
| Del Rey, NL | 2 |
| Juri, C | 1 |
| Collantes, M | 1 |
| Pineda-Pardo, JA | 1 |
| Trigo-Damas, I | 1 |
| Iglesias, E | 1 |
| Hernández, LF | 1 |
| Rodríguez-Rojas, R | 1 |
| Gago, B | 1 |
| Ecay, M | 1 |
| Prieto, E | 1 |
| García-Cabezas, MÁ | 1 |
| Cavada, C | 2 |
| Rodríguez-Oroz, MC | 2 |
| Peñuelas, I | 1 |
| Obeso, JA | 4 |
| Munakata, H | 1 |
| Ishikawa, R | 1 |
| Saitoh, T | 2 |
| Kambe, T | 1 |
| Chiba, T | 1 |
| Taguchi, K | 2 |
| Abe, K | 2 |
| Smeyne, RJ | 8 |
| Eells, JB | 1 |
| Chatterjee, D | 1 |
| Byrne, M | 1 |
| Akula, SM | 1 |
| Sriramula, S | 1 |
| O'Rourke, DP | 1 |
| Schmidt, P | 1 |
| Palese, F | 1 |
| Pontis, S | 1 |
| Realini, N | 1 |
| Torrens, A | 1 |
| Ahmed, F | 1 |
| Assogna, F | 1 |
| Pellicano, C | 1 |
| Bossù, P | 1 |
| Spalletta, G | 1 |
| Green, K | 1 |
| Piomelli, D | 1 |
| Shen, J | 1 |
| Zha, Q | 1 |
| Yang, QH | 1 |
| Zhou, YQ | 1 |
| Liang, X | 1 |
| Chen, YJ | 2 |
| Qi, GX | 1 |
| Zhang, XJ | 1 |
| Yao, WB | 1 |
| Gao, XD | 1 |
| Chen, S | 1 |
| Heng, Y | 3 |
| Li, YY | 1 |
| Wen, L | 1 |
| Yan, JQ | 1 |
| Chen, NH | 3 |
| Yuan, YH | 3 |
| Lin, HC | 3 |
| Wu, YH | 3 |
| Huang, CW | 3 |
| Ker, MD | 3 |
| Bourque, M | 5 |
| Grégoire, L | 11 |
| Patel, W | 3 |
| Dickens, D | 3 |
| Snodgrass, R | 3 |
| Di Paolo, T | 19 |
| Briñez-Gallego, P | 1 |
| da Costa Silva, DG | 1 |
| Cordeiro, MF | 1 |
| Horn, AP | 1 |
| Hort, MA | 1 |
| Qi, Y | 1 |
| Zhang, Z | 6 |
| Li, Y | 4 |
| Zhao, G | 1 |
| Huang, J | 2 |
| Xue, J | 1 |
| Tang, X | 1 |
| Wang, H | 1 |
| Fukunaga, K | 1 |
| Cheng, A | 1 |
| Arimura, N | 1 |
| Yoshino, H | 1 |
| Sasaki, T | 1 |
| Kawahata, I | 1 |
| Usenko, T | 1 |
| Bezrukova, A | 1 |
| Rudenok, MM | 1 |
| Basharova, K | 1 |
| Shadrina, MI | 1 |
| Slominsky, PA | 1 |
| Zakharova, E | 1 |
| Pchelina, S | 1 |
| Tang, L | 1 |
| Xu, N | 1 |
| Huang, M | 1 |
| Yi, W | 1 |
| Sang, X | 1 |
| Shao, M | 1 |
| Hao, ZZ | 1 |
| Liu, R | 1 |
| Shen, Y | 1 |
| Yue, F | 1 |
| Liu, X | 4 |
| Xu, C | 1 |
| Liu, S | 3 |
| Jarras, H | 1 |
| Poirier, AA | 1 |
| Morissette, M | 12 |
| Coulombe, K | 1 |
| Soulet, D | 1 |
| Xu, M | 1 |
| Bohlen, JK | 1 |
| Moore, C | 4 |
| Nipper, MA | 1 |
| Finn, DA | 1 |
| Jones, CE | 1 |
| Lim, MM | 1 |
| Meshul, CK | 7 |
| Jiménez-Sánchez, L | 1 |
| Monje, MHG | 1 |
| Nurmaganbetov, ZS | 1 |
| Arystan, LI | 1 |
| Muldaeva, GM | 1 |
| Haydargalieva, LS | 1 |
| Adekenov, SM | 1 |
| Ando, K | 3 |
| Inoue, T | 2 |
| Hikishima, K | 1 |
| Komaki, Y | 1 |
| Kawai, K | 1 |
| Inoue, R | 1 |
| Nishime, C | 1 |
| Nishinaka, E | 1 |
| Urano, K | 1 |
| Okano, H | 1 |
| Vivacqua, G | 1 |
| Biagioni, F | 2 |
| Busceti, CL | 4 |
| Ferrucci, M | 2 |
| Madonna, M | 1 |
| Ryskalin, L | 2 |
| Yu, S | 1 |
| D'Este, L | 1 |
| Fornai, F | 4 |
| Yeo, S | 2 |
| Song, J | 1 |
| Lim, S | 2 |
| Rao, SP | 1 |
| Sharma, N | 1 |
| Kalivendi, SV | 2 |
| Darbin, O | 1 |
| Hatanaka, N | 1 |
| Takara, S | 1 |
| Kaneko, N | 1 |
| Chiken, S | 1 |
| Naritoku, D | 1 |
| Martino, A | 1 |
| Nambu, A | 3 |
| Liu, Q | 2 |
| Guo, X | 1 |
| Huang, Z | 1 |
| He, Q | 1 |
| Zhu, D | 1 |
| Zhang, S | 1 |
| Peng, Z | 1 |
| Che, Y | 1 |
| Feng, X | 1 |
| Marchetti, B | 2 |
| Tirolo, C | 2 |
| L'Episcopo, F | 2 |
| Caniglia, S | 2 |
| Testa, N | 2 |
| Smith, JA | 2 |
| Pluchino, S | 1 |
| Serapide, MF | 1 |
| Massaquoi, MS | 1 |
| Liguore, WA | 1 |
| Churchill, MJ | 3 |
| Melrose, HL | 1 |
| Moreau, C | 1 |
| Rolland, AS | 2 |
| Pioli, E | 1 |
| Odou, P | 1 |
| Barthelemy, C | 1 |
| Lannoy, D | 1 |
| Demailly, A | 1 |
| Carta, N | 1 |
| Deramecourt, V | 1 |
| Auger, F | 1 |
| Kuchcinski, G | 1 |
| Laloux, C | 2 |
| Defebvre, L | 1 |
| Bordet, R | 3 |
| Duce, J | 1 |
| Devedjian, JC | 1 |
| Bezard, E | 20 |
| Fisichella, M | 1 |
| Devos, D | 1 |
| Qin, L | 3 |
| Xie, J | 1 |
| Li, J | 3 |
| Wang, C | 2 |
| Saegusa, H | 1 |
| Li, X | 3 |
| Wang, X | 4 |
| Kayakiri, M | 1 |
| Tanabe, T | 1 |
| Hamadjida, A | 3 |
| Frouni, I | 3 |
| Kwan, C | 4 |
| Bédard, D | 3 |
| Zhao, J | 1 |
| Yang, M | 1 |
| Pei, X | 1 |
| Zhu, X | 4 |
| Liu, Y | 4 |
| Jin, W | 1 |
| Deng, Z | 1 |
| Zhang, Q | 3 |
| Kucheryanu, VG | 1 |
| Vetrile, LA | 1 |
| Zakharova, IA | 1 |
| Voronina, NA | 1 |
| Chen, Z | 2 |
| Yuan, J | 1 |
| Huang, X | 2 |
| Zheng, M | 1 |
| Chen, M | 1 |
| Fan, Y | 2 |
| Shi, D | 1 |
| Borgognon, S | 1 |
| Cottet, J | 1 |
| Badoud, S | 1 |
| Bloch, J | 2 |
| Brunet, JF | 1 |
| Rouiller, EM | 1 |
| Bonifácio, MJ | 1 |
| Sousa, F | 1 |
| Soares-da-Silva, P | 1 |
| Deffains, M | 1 |
| Canron, MH | 2 |
| Teil, M | 1 |
| Dehay, B | 1 |
| Fernagut, PO | 2 |
| Mailman, RB | 1 |
| Yang, Y | 2 |
| Yan, J | 1 |
| Liu, A | 1 |
| Wu, J | 3 |
| Fan, H | 2 |
| Shen, M | 1 |
| Lai, X | 1 |
| Ma, H | 1 |
| Sun, W | 1 |
| Yang, J | 1 |
| Xu, Y | 2 |
| Wu, WJ | 1 |
| Lu, CW | 1 |
| Wang, SE | 1 |
| Lin, CL | 1 |
| Su, LY | 1 |
| Wu, CH | 1 |
| Merghani, MM | 1 |
| Ardah, MT | 1 |
| Al Shamsi, M | 1 |
| Kitada, T | 1 |
| Haque, ME | 1 |
| Villalba, RM | 2 |
| Behnke, JA | 1 |
| Pare, JF | 1 |
| Smith, Y | 3 |
| Cao, H | 1 |
| Han, X | 1 |
| Jia, Y | 1 |
| Zhang, B | 1 |
| Cuenca-Bermejo, L | 1 |
| Pizzichini, E | 1 |
| Gonçalves, VC | 1 |
| Guillén-Díaz, M | 1 |
| Aguilar-Moñino, E | 1 |
| Sánchez-Rodrigo, C | 1 |
| González-Cuello, AM | 1 |
| Fernández-Villalba, E | 7 |
| Herrero, MT | 8 |
| Bogdanov, V | 1 |
| Kim, A | 1 |
| Nodel, M | 1 |
| Pavlenko, T | 1 |
| Pavlova, E | 1 |
| Blokhin, V | 1 |
| Chesnokova, N | 1 |
| Ugrumov, M | 1 |
| Liu, W | 3 |
| Song, S | 1 |
| Fu, J | 1 |
| Hayashi, T | 2 |
| Mizuno, K | 1 |
| Hattori, S | 1 |
| Fujisaki, H | 1 |
| Ikejima, T | 1 |
| Pinelli, R | 1 |
| Bertelli, M | 1 |
| Scaffidi, E | 1 |
| Bai, X | 1 |
| Dong, Q | 1 |
| Zhao, L | 2 |
| Yao, Y | 1 |
| Wang, B | 1 |
| Huang, Q | 1 |
| Wei, Z | 2 |
| Ma, S | 2 |
| Woodgett, JR | 1 |
| Li, M | 2 |
| Houser, MC | 1 |
| Caudle, WM | 3 |
| Chang, J | 1 |
| Kannarkat, GT | 1 |
| Kelly, SD | 1 |
| Oliver, D | 1 |
| Joers, V | 1 |
| Shannon, KM | 1 |
| Keshavarzian, A | 1 |
| Tansey, MG | 1 |
| Carelli, S | 2 |
| Giallongo, T | 2 |
| Viaggi, C | 4 |
| Latorre, E | 1 |
| Gombalova, Z | 2 |
| Raspa, A | 1 |
| Mazza, M | 2 |
| Vaglini, F | 4 |
| Di Giulio, AM | 2 |
| Gorio, A | 1 |
| Shi, L | 1 |
| Luo, Q | 1 |
| Chen, X | 2 |
| Zeng, W | 1 |
| Fatkullina, LD | 1 |
| Molochkina, EM | 1 |
| Kozachenko, AI | 1 |
| Nagler, LG | 1 |
| Burlakova, EB | 1 |
| Zhang, QS | 3 |
| Mou, Z | 1 |
| Huang, JY | 1 |
| Finkelstein, DI | 3 |
| Billings, JL | 1 |
| Adlard, PA | 2 |
| Ayton, S | 2 |
| Sedjahtera, A | 1 |
| Masters, CL | 1 |
| Wilkins, S | 1 |
| Shackleford, DM | 1 |
| Charman, SA | 1 |
| Bal, W | 1 |
| Zawisza, IA | 1 |
| Kurowska, E | 1 |
| Gundlach, AL | 1 |
| Bush, AI | 2 |
| Hare, DJ | 1 |
| Doble, PA | 1 |
| Crawford, S | 1 |
| Gautier, EC | 1 |
| Parsons, J | 1 |
| Huggins, P | 1 |
| Barnham, KJ | 1 |
| Cherny, RA | 3 |
| Son, HJ | 2 |
| Han, SH | 1 |
| Lee, JA | 1 |
| Shin, EJ | 2 |
| Hwang, O | 2 |
| Celorrio, M | 1 |
| Rojo-Bustamante, E | 1 |
| Fernández-Suárez, D | 1 |
| Sáez, E | 1 |
| Estella-Hermoso de Mendoza, A | 1 |
| Müller, CE | 2 |
| Ramírez, MJ | 1 |
| Oyarzábal, J | 1 |
| Franco, R | 2 |
| Aymerich, MS | 1 |
| Buneeva, OA | 1 |
| Kopylov, AT | 1 |
| Nerobkova, LN | 1 |
| Kapitsa, IG | 1 |
| Zgoda, VG | 1 |
| Medvedev, AE | 1 |
| Zhao, TT | 1 |
| Kim, KS | 1 |
| Shin, KS | 1 |
| Park, HJ | 3 |
| Kim, HJ | 1 |
| Lee, KE | 1 |
| Lee, MK | 1 |
| Singh, B | 1 |
| Pandey, S | 1 |
| Yadav, SK | 1 |
| Verma, R | 1 |
| Singh, SP | 2 |
| Mahdi, AA | 1 |
| Météreau, E | 1 |
| Beaudoin-Gobert, M | 1 |
| Duperrier, S | 1 |
| Thobois, S | 1 |
| Tremblay, L | 3 |
| Sgambato-Faure, V | 1 |
| Ren, M | 1 |
| Guo, Y | 1 |
| Wei, X | 1 |
| Yan, S | 1 |
| Qin, Y | 1 |
| Jiang, F | 1 |
| Lou, H | 1 |
| Kabel, AM | 1 |
| Omar, MS | 1 |
| Alhadhrami, A | 1 |
| Alharthi, SS | 1 |
| Alrobaian, MM | 1 |
| Lu, Z | 1 |
| Bhattacharya, S | 1 |
| Ma, Y | 3 |
| Dunn, AR | 2 |
| Bradner, JM | 1 |
| Scimemi, A | 1 |
| Miller, GW | 5 |
| Traynelis, SF | 2 |
| Wichmann, T | 4 |
| Hammond, SL | 1 |
| Popichak, KA | 1 |
| Hunt, LG | 1 |
| Richman, EH | 1 |
| Damale, PU | 1 |
| Chong, EKP | 1 |
| Backos, DS | 1 |
| Safe, S | 1 |
| Tjalkens, RB | 1 |
| Sekar, S | 1 |
| Mani, S | 1 |
| Rajamani, B | 1 |
| Manivasagam, T | 3 |
| Thenmozhi, AJ | 1 |
| Bhat, A | 1 |
| Ray, B | 1 |
| Essa, MM | 3 |
| Guillemin, GJ | 2 |
| Chidambaram, SB | 1 |
| Seo, J | 1 |
| Lee, Y | 1 |
| Kim, BS | 1 |
| Park, J | 1 |
| Yang, S | 2 |
| Yoon, HJ | 1 |
| Yoo, J | 1 |
| Park, HS | 1 |
| Hong, JJ | 1 |
| Koo, BS | 1 |
| Baek, SH | 1 |
| Jeon, CY | 1 |
| Huh, JW | 1 |
| Kim, YH | 1 |
| Park, SJ | 1 |
| Won, J | 1 |
| Ahn, YJ | 1 |
| Kim, K | 1 |
| Jeong, KJ | 1 |
| Kang, P | 1 |
| Lee, DS | 1 |
| Lim, SM | 1 |
| Jin, YB | 1 |
| Lee, SR | 1 |
| Song, DH | 1 |
| Kim, GJ | 1 |
| Lee, KJ | 1 |
| Shin, JS | 1 |
| Kim, DH | 1 |
| Park, BJ | 1 |
| An, JH | 1 |
| Gil-Martínez, AL | 1 |
| Cuenca, L | 1 |
| Sánchez, C | 1 |
| Estrada, C | 1 |
| Rey, F | 1 |
| Gorio, MCF | 1 |
| Chang, HC | 1 |
| Liu, KF | 1 |
| Teng, CJ | 1 |
| Lai, SC | 1 |
| Yang, SE | 1 |
| Ching, H | 1 |
| Wu, CR | 1 |
| Xue, X | 1 |
| Zhang, W | 6 |
| Zhu, J | 2 |
| Zhou, S | 2 |
| Xu, Z | 1 |
| Hu, G | 2 |
| Su, C | 1 |
| Cheng, C | 1 |
| Selvaraj, V | 1 |
| Venkatasubramanian, H | 1 |
| Ilango, K | 1 |
| Santhakumar, K | 1 |
| Lv, R | 1 |
| Du, L | 1 |
| Zhou, F | 1 |
| Zhang, L | 2 |
| Burks, S | 1 |
| Raymick, J | 1 |
| Robinson, B | 1 |
| Hanig, J | 1 |
| Sarkar, S | 1 |
| Rai, SN | 1 |
| Zahra, W | 1 |
| Singh, SS | 1 |
| Birla, H | 1 |
| Keswani, C | 1 |
| Dilnashin, H | 1 |
| Rathore, AS | 1 |
| Singh, R | 2 |
| Singh, RK | 2 |
| Kim, SJ | 2 |
| Ryu, MJ | 1 |
| Han, J | 1 |
| Jang, Y | 1 |
| Lee, MJ | 1 |
| Ju, X | 1 |
| Ryu, I | 1 |
| Lee, YL | 1 |
| Oh, E | 1 |
| Chung, W | 1 |
| Heo, JY | 1 |
| Kweon, GR | 1 |
| Sampath, C | 1 |
| Kalpana, R | 1 |
| Ansah, T | 1 |
| Charlton, C | 1 |
| Hale, A | 1 |
| Channon, KM | 1 |
| Srinivasan, S | 1 |
| Gangula, PR | 1 |
| Rosenblad, C | 1 |
| Pioli, EY | 1 |
| Dovero, S | 8 |
| Antunes, AS | 1 |
| Agúndez, L | 1 |
| Bardelli, M | 1 |
| Linden, RM | 1 |
| Henckaerts, E | 1 |
| Björklund, A | 2 |
| Björklund, T | 1 |
| Noelker, C | 2 |
| Morel, L | 1 |
| Lescot, T | 1 |
| Osterloh, A | 1 |
| Alvarez-Fischer, D | 3 |
| Breloer, M | 1 |
| Henze, C | 1 |
| Depboylu, C | 1 |
| Skrzydelski, D | 1 |
| Michel, PP | 2 |
| Dodel, RC | 1 |
| Lu, L | 3 |
| Hirsch, EC | 10 |
| Hunot, S | 2 |
| Hartmann, A | 3 |
| Castro, AA | 3 |
| Wiemes, BP | 1 |
| Matheus, FC | 2 |
| Lapa, FR | 1 |
| Viola, GG | 1 |
| Santos, AR | 2 |
| Tasca, CI | 3 |
| Prediger, RD | 4 |
| George, JL | 1 |
| Cartelli, D | 1 |
| Casagrande, F | 1 |
| Bucci, D | 2 |
| Molinaro, G | 2 |
| Traficante, A | 1 |
| Passarella, D | 1 |
| Giavini, E | 1 |
| Pezzoli, G | 1 |
| Battaglia, G | 3 |
| Cappelletti, G | 1 |
| Sánchez, MG | 1 |
| Grabli, D | 1 |
| Karachi, C | 2 |
| Folgoas, E | 1 |
| Monfort, M | 1 |
| Tande, D | 2 |
| Clark, S | 1 |
| Civelli, O | 1 |
| François, C | 3 |
| Campello, L | 1 |
| Esteve-Rudd, J | 1 |
| Bru-Martínez, R | 1 |
| Cuenca, N | 1 |
| Martín-Nieto, J | 1 |
| Dagda, RK | 1 |
| Das Banerjee, T | 1 |
| Janda, E | 1 |
| Bonaventura, J | 1 |
| Rico, AJ | 2 |
| Moreno, E | 1 |
| Sierra, S | 2 |
| Sánchez, M | 1 |
| Luquin, N | 2 |
| Farré, D | 1 |
| Martínez-Pinilla, E | 1 |
| Cortés, A | 1 |
| Mallol, J | 1 |
| Armentero, MT | 1 |
| Pinna, A | 1 |
| Canela, EI | 1 |
| Lluís, C | 1 |
| McCormick, PJ | 1 |
| Lanciego, JL | 3 |
| Casadó, V | 1 |
| Kim, HG | 2 |
| Park, G | 1 |
| Piao, Y | 1 |
| Kang, MS | 1 |
| Pak, YK | 1 |
| Hong, SP | 1 |
| Oh, MS | 2 |
| Morin, N | 3 |
| Jourdain, VA | 2 |
| Fifel, K | 1 |
| Vezoli, J | 1 |
| Dzahini, K | 1 |
| Claustrat, B | 1 |
| Leviel, V | 1 |
| Kennedy, H | 1 |
| Procyk, E | 1 |
| Dkhissi-Benyahya, O | 1 |
| Gronfier, C | 1 |
| Cooper, HM | 1 |
| Oeckl, P | 1 |
| Scheffold, A | 1 |
| Lechel, A | 1 |
| Rudolph, KL | 1 |
| Ferger, B | 4 |
| Swanson, C | 1 |
| Emborg, M | 1 |
| Ho, SC | 2 |
| Hsu, CC | 3 |
| Yu, CH | 1 |
| Huang, WN | 1 |
| Tikhonova, MA | 2 |
| Ho, MC | 1 |
| Hung, CS | 1 |
| Amstislavskaya, TG | 2 |
| Ho, YJ | 2 |
| Pawlak, CR | 1 |
| Lai, TJ | 1 |
| Philippens, IH | 4 |
| Joosen, MJ | 1 |
| Ahnaou, A | 1 |
| Andres, I | 1 |
| Drinkenburg, WP | 1 |
| Tian, L | 2 |
| Karimi, M | 2 |
| Brown, CA | 1 |
| Loftin, SK | 1 |
| Perlmutter, JS | 2 |
| Smith, ML | 1 |
| King, J | 1 |
| Dent, L | 1 |
| Mackey, V | 1 |
| Muthian, G | 1 |
| Griffin, B | 1 |
| Charlton, CG | 1 |
| He, LX | 1 |
| Huang, SN | 1 |
| Gong, LJ | 1 |
| Lv, YY | 1 |
| Qian, ZM | 1 |
| Wang, S | 3 |
| He, H | 1 |
| Chen, L | 3 |
| Chen, J | 1 |
| Lohr, KM | 1 |
| Bernstein, AI | 1 |
| Stout, KA | 1 |
| Lazo, CR | 1 |
| Alter, SP | 1 |
| Wang, M | 2 |
| Fan, X | 1 |
| Hess, EJ | 1 |
| Yi, H | 1 |
| Vecchio, LM | 1 |
| Goldstein, DS | 1 |
| Guillot, TS | 1 |
| Salahpour, A | 1 |
| Dugan, LL | 1 |
| Quick, KL | 1 |
| Hardt, JI | 1 |
| Brown, C | 1 |
| Loftin, S | 1 |
| Flores, H | 1 |
| Moerlein, SM | 1 |
| Polich, J | 1 |
| Tabbal, SD | 1 |
| Mink, JW | 1 |
| Qin, X | 1 |
| Wu, Q | 1 |
| Lin, L | 1 |
| Sun, A | 1 |
| Cao, X | 2 |
| Gao, T | 1 |
| Luo, P | 1 |
| Nash, KR | 1 |
| Moran, P | 1 |
| Finneran, DJ | 1 |
| Hudson, C | 1 |
| Robinson, J | 1 |
| Morgan, D | 1 |
| Bickford, PC | 1 |
| Kim, BW | 1 |
| Koppula, S | 1 |
| Park, SY | 1 |
| Kim, YS | 3 |
| Park, PJ | 1 |
| Lim, JH | 1 |
| Kim, IS | 1 |
| Choi, DK | 5 |
| Itoh, T | 1 |
| El Massri, N | 2 |
| Johnstone, DM | 3 |
| Peoples, CL | 1 |
| Moro, C | 3 |
| Reinhart, F | 2 |
| Torres, N | 3 |
| Stone, J | 3 |
| Benabid, AL | 5 |
| Mitrofanis, J | 5 |
| Sharma, S | 1 |
| Deshmukh, R | 1 |
| Tyagi, RK | 1 |
| Bisht, R | 1 |
| Pant, J | 1 |
| Kumar, P | 2 |
| Majeed, AB | 1 |
| Prakash, A | 1 |
| Zhu, G | 1 |
| He, L | 2 |
| Hong, X | 2 |
| Naskar, A | 1 |
| Prabhakar, V | 1 |
| Dutta, D | 1 |
| Mohanakumar, KP | 5 |
| Jing, H | 1 |
| Yang, H | 1 |
| Liu, Z | 1 |
| Guo, H | 3 |
| Chai, L | 1 |
| Hu, L | 2 |
| Bao, XQ | 1 |
| Wu, LY | 2 |
| Wang, XL | 1 |
| Zhang, D | 2 |
| Erekat, NS | 1 |
| Cannella, M | 1 |
| Motolese, M | 1 |
| Gradini, R | 1 |
| Bruno, V | 1 |
| Nicoletti, F | 3 |
| Bentea, E | 1 |
| Sconce, MD | 2 |
| Van Liefferinge, J | 1 |
| Sato, H | 1 |
| Massie, A | 1 |
| Lecca, D | 1 |
| Nevin, DK | 1 |
| Mulas, G | 1 |
| Casu, MA | 1 |
| Diana, A | 1 |
| Rossi, D | 1 |
| Sacchetti, G | 1 |
| Carta, AR | 1 |
| Greene, RE | 1 |
| Shi, F | 1 |
| Yu, B | 1 |
| Zhao, Y | 1 |
| Xi, J | 1 |
| Xiao, B | 1 |
| Ma, C | 1 |
| Höllerhage, M | 1 |
| Vulinovic, F | 1 |
| Sturn, A | 1 |
| Roscher, R | 1 |
| Höglinger, GU | 1 |
| Oertel, WH | 2 |
| Andreas, H | 1 |
| Jalewa, J | 1 |
| Sharma, M | 1 |
| Li, G | 1 |
| Hölscher, C | 2 |
| Nie, S | 1 |
| Chen, G | 1 |
| Ma, K | 1 |
| Han, C | 1 |
| Guo, Z | 2 |
| Ye, K | 2 |
| Wang, ZH | 1 |
| Zhang, JL | 1 |
| Duan, YL | 1 |
| Li, GF | 1 |
| Zheng, DL | 1 |
| Pasquereau, B | 1 |
| DeLong, MR | 1 |
| Turner, RS | 2 |
| Singhal, NK | 1 |
| Agarwal, S | 1 |
| Bhatnagar, P | 1 |
| Tiwari, MN | 1 |
| Tiwari, SK | 1 |
| Srivastava, G | 1 |
| Brashket, S | 1 |
| Patel, DK | 2 |
| Chaturvedi, RK | 1 |
| Singh, MP | 2 |
| Gupta, KC | 1 |
| Tereshchenko, LV | 2 |
| Anisimov, VN | 1 |
| Shul'govsky, VV | 1 |
| Latanov, AV | 2 |
| McGregor, M | 1 |
| Bordia, T | 1 |
| Perez, XA | 2 |
| McIntosh, JM | 3 |
| Decker, MW | 1 |
| Quik, M | 6 |
| Mu, Z | 1 |
| Hu, JF | 1 |
| Franke, SK | 1 |
| van Kesteren, RE | 1 |
| Hofman, S | 1 |
| Wubben, JA | 1 |
| Smit, AB | 1 |
| Luo, D | 1 |
| Shi, Y | 1 |
| Lin, Q | 2 |
| Sun, Y | 2 |
| Yan, Q | 1 |
| Zhang, H | 1 |
| Guan, Q | 1 |
| Chen, H | 1 |
| Yang, L | 7 |
| Yan, Z | 1 |
| Ahuja, M | 1 |
| Ammal Kaidery, N | 1 |
| Calingasan, N | 1 |
| Smirnova, N | 1 |
| Gaisin, A | 1 |
| Gaisina, IN | 1 |
| Gazaryan, I | 1 |
| Hushpulian, DM | 1 |
| Kaddour-Djebbar, I | 1 |
| Bollag, WB | 1 |
| Morgan, JC | 1 |
| Ratan, RR | 1 |
| Starkov, AA | 2 |
| Beal, MF | 6 |
| Thomas, B | 2 |
| Darlot, F | 1 |
| Chabrol, C | 2 |
| Agay, D | 1 |
| Auboiroux, V | 1 |
| Kammermeier, S | 1 |
| Pittard, D | 1 |
| Hamada, I | 1 |
| Nielsen, MS | 1 |
| Glud, AN | 1 |
| Møller, A | 1 |
| Mogensen, P | 1 |
| Bender, D | 1 |
| Sørensen, JC | 1 |
| Doudet, D | 1 |
| Bjarkam, CR | 1 |
| Kim, D | 1 |
| Jeon, H | 1 |
| Ryu, S | 1 |
| Koo, S | 1 |
| Ha, KT | 1 |
| Kim, S | 1 |
| Zhao, YF | 1 |
| Xi, JY | 1 |
| Yu, WB | 1 |
| Xiao, BG | 1 |
| Massri, NE | 1 |
| Molet, J | 1 |
| Janakiraman, U | 1 |
| Justin Thenmozhi, A | 1 |
| Dhanalakshmi, C | 1 |
| Song, BJ | 1 |
| Kanazawa, M | 1 |
| Ohba, H | 1 |
| Nishiyama, S | 2 |
| Kakiuchi, T | 2 |
| Tsukada, H | 2 |
| Langston, JW | 9 |
| Bian, M | 2 |
| Yu, M | 4 |
| Gao, H | 1 |
| Huang, Y | 3 |
| Deng, C | 1 |
| Gao, Y | 1 |
| Sun, F | 1 |
| Huang, F | 4 |
| Ding, F | 1 |
| Luan, L | 1 |
| Ai, Y | 1 |
| Walton, A | 1 |
| Gerhardt, GA | 1 |
| Gash, DM | 1 |
| Grondin, R | 4 |
| Arias, RL | 1 |
| Sung, ML | 1 |
| Vasylyev, D | 1 |
| Zhang, MY | 1 |
| Albinson, K | 1 |
| Kubek, K | 1 |
| Kagan, N | 1 |
| Beyer, C | 1 |
| Dwyer, JM | 1 |
| Zaleska, MM | 1 |
| Bowlby, MR | 1 |
| Dunlop, J | 1 |
| Monaghan, M | 1 |
| Panaro, MA | 1 |
| Lofrumento, DD | 1 |
| Saponaro, C | 1 |
| De Nuccio, F | 1 |
| Cianciulli, A | 1 |
| Mitolo, V | 1 |
| Nicolardi, G | 1 |
| Suleman, NK | 1 |
| Flores, J | 1 |
| Tanko, JM | 1 |
| Isin, EM | 1 |
| Castagnoli, N | 4 |
| Guerreiro, S | 1 |
| Saurini, F | 1 |
| Marien, M | 1 |
| Sokoloff, P | 1 |
| Dorval, AD | 1 |
| Russo, GS | 2 |
| Hashimoto, T | 5 |
| Xu, W | 2 |
| Grill, WM | 1 |
| Vitek, JL | 4 |
| Boger, HA | 1 |
| Middaugh, LD | 1 |
| Zaman, V | 1 |
| Hoffer, B | 1 |
| Granholm, AC | 1 |
| Domino, EF | 2 |
| Ni, L | 1 |
| Muñoz, A | 1 |
| Gardoni, F | 1 |
| Marcello, E | 1 |
| Qin, C | 3 |
| Carlsson, T | 1 |
| Kirik, D | 1 |
| Di Luca, M | 1 |
| Carta, M | 1 |
| Muroyama, A | 1 |
| Inaka, M | 1 |
| Matsushima, H | 1 |
| Sugino, H | 1 |
| Marunaka, Y | 1 |
| Mitsumoto, Y | 2 |
| Liu, J | 4 |
| Wang, YY | 2 |
| Liu, L | 2 |
| Wang, QD | 1 |
| Yuan, ZY | 2 |
| Zhang, ZX | 2 |
| Gu, P | 2 |
| Wang, MW | 2 |
| Samantaray, S | 2 |
| Butler, JT | 1 |
| Ray, SK | 2 |
| Banik, NL | 2 |
| Campos-Romo, A | 1 |
| Ojeda-Flores, R | 1 |
| Moreno-Briseño, P | 1 |
| Fernandez-Ruiz, J | 2 |
| Chaumette, T | 1 |
| Lebouvier, T | 1 |
| Aubert, P | 1 |
| Lardeux, B | 1 |
| Accary, D | 1 |
| Bruley des Varannes, S | 1 |
| Derkinderen, P | 1 |
| Neunlist, M | 1 |
| Christine, CW | 1 |
| Starr, PA | 1 |
| Visanji, NP | 4 |
| Fox, SH | 8 |
| Johnston, T | 1 |
| Reyes, G | 1 |
| Millan, MJ | 2 |
| Brotchie, JM | 11 |
| Sado, M | 1 |
| Yamasaki, Y | 1 |
| Iwanaga, T | 1 |
| Onaka, Y | 1 |
| Ibuki, T | 1 |
| Nishihara, S | 1 |
| Mizuguchi, H | 1 |
| Momota, H | 1 |
| Kishibuchi, R | 1 |
| Wada, D | 1 |
| Kitagawa, H | 1 |
| Watanabe, TK | 1 |
| Samadi, P | 3 |
| Graham, J | 1 |
| Bédard, PJ | 8 |
| Bartoszyk, GD | 1 |
| Pardini, C | 3 |
| Caramelli, A | 2 |
| Corsini, GU | 3 |
| Dodd, CA | 1 |
| Klein, BG | 1 |
| Astradsson, A | 1 |
| Jenkins, BG | 2 |
| Choi, JK | 1 |
| Hallett, PJ | 3 |
| Levesque, MA | 1 |
| McDowell, JS | 1 |
| Brownell, AL | 2 |
| Spealman, RD | 1 |
| Isacson, O | 2 |
| Singh, S | 2 |
| Singh, K | 1 |
| Gupta, SP | 1 |
| Singh, VK | 1 |
| Luquin, MR | 2 |
| Vazquez-Claverie, M | 2 |
| Zhou, H | 1 |
| Hoang, T | 1 |
| Nagai, M | 1 |
| Wu, DC | 5 |
| Nagata, T | 1 |
| Prou, D | 1 |
| Wilson, GL | 1 |
| Vila, M | 8 |
| Jackson-Lewis, V | 14 |
| Dawson, VL | 3 |
| Dawson, TM | 3 |
| Chesselet, MF | 1 |
| Przedborski, S | 16 |
| Bian, MJ | 1 |
| Li, LM | 1 |
| Fei, J | 3 |
| Bousquet, M | 1 |
| Gibrat, C | 1 |
| Saint-Pierre, M | 1 |
| Julien, C | 1 |
| Calon, F | 5 |
| Cicchetti, F | 1 |
| Nayyar, T | 1 |
| Bubser, M | 1 |
| Ferguson, MC | 1 |
| Neely, MD | 2 |
| Shawn Goodwin, J | 1 |
| Montine, TJ | 1 |
| Deutch, AY | 2 |
| Ansah, TA | 1 |
| Borah, A | 2 |
| Kim, ST | 3 |
| Choi, JH | 1 |
| Ji, IJ | 1 |
| Silverdale, MA | 2 |
| Kobylecki, C | 1 |
| Dunah, AW | 1 |
| Ravenscroft, P | 4 |
| Ghosh, A | 2 |
| Roy, A | 1 |
| Matras, J | 1 |
| Brahmachari, S | 1 |
| Gendelman, HE | 2 |
| Pahan, K | 1 |
| Yokoyama, H | 5 |
| Kuroiwa, H | 4 |
| Tsukada, T | 3 |
| Uchida, H | 4 |
| Kato, H | 9 |
| Araki, T | 11 |
| Hong, MS | 1 |
| Park, HK | 3 |
| Yang, JS | 1 |
| Kim, SN | 2 |
| Park, JY | 2 |
| Song, JY | 1 |
| Jo, DJ | 1 |
| Park, SW | 1 |
| HwanYun, D | 1 |
| Ban, JY | 1 |
| Chung, JH | 1 |
| Doo, AR | 1 |
| Moon, W | 1 |
| Yin, CS | 1 |
| Chae, Y | 1 |
| Lee, H | 3 |
| Cano-Jaimez, M | 1 |
| Pérez-Sánchez, F | 1 |
| Milán, M | 1 |
| Buendía, P | 1 |
| Ambrosio, S | 1 |
| Fariñas, I | 1 |
| Malagelada, C | 1 |
| Jin, ZH | 1 |
| Greene, LA | 2 |
| Gerecke, KM | 1 |
| Jiao, Y | 3 |
| Pani, A | 1 |
| Pagala, V | 1 |
| Garcia, BG | 1 |
| Corona, JC | 1 |
| Gimenez-Cassina, A | 1 |
| Lim, F | 1 |
| Díaz-Nido, J | 1 |
| Subramanian, T | 1 |
| Lieu, CA | 1 |
| Guttalu, K | 1 |
| Berg, D | 1 |
| Antzoulatos, E | 1 |
| Jakowec, MW | 1 |
| Petzinger, GM | 1 |
| Wood, RI | 1 |
| Ahmed, MR | 1 |
| Berthet, A | 2 |
| Bychkov, E | 1 |
| Porras, G | 2 |
| Bioulac, BH | 3 |
| Carl, YT | 1 |
| Bloch, B | 3 |
| Kook, S | 1 |
| Aubert, I | 3 |
| Doudnikoff, E | 2 |
| Gurevich, VV | 1 |
| Gurevich, EV | 1 |
| Reksidler, AB | 1 |
| Lima, MM | 1 |
| Dombrowski, PA | 1 |
| Barnabé, GF | 1 |
| Andersen, ML | 1 |
| Tufik, S | 1 |
| Vital, MA | 2 |
| Gouty, S | 1 |
| Brown, JM | 1 |
| Rosenberger, J | 1 |
| Cox, BM | 1 |
| Yano, R | 3 |
| Kasahara, J | 2 |
| Kimoto, H | 2 |
| Kreisler, A | 1 |
| Duhamel, A | 1 |
| Vanbesien-Mailliot, C | 1 |
| Destée, A | 2 |
| Phani, S | 1 |
| Gonye, G | 1 |
| Iacovitti, L | 1 |
| Lin, CJ | 1 |
| Tai, Y | 1 |
| Huang, MT | 1 |
| Tsai, YF | 1 |
| Hsu, HJ | 1 |
| Tzen, KY | 1 |
| Liou, HH | 1 |
| Saiki, H | 1 |
| Takahashi, R | 3 |
| Takahashi, J | 1 |
| Bazzu, G | 1 |
| Calia, G | 1 |
| Puggioni, G | 1 |
| Spissu, Y | 1 |
| Rocchitta, G | 1 |
| Debetto, P | 1 |
| Grigoletto, J | 1 |
| Zusso, M | 1 |
| Migheli, R | 1 |
| Serra, PA | 2 |
| Desole, MS | 1 |
| Miele, E | 2 |
| Ma, QY | 1 |
| Geng, Y | 1 |
| Cui, DS | 1 |
| Ma, L | 1 |
| Zhang, BH | 1 |
| Zhou, MG | 1 |
| Zhu, AP | 1 |
| Sallinen, V | 1 |
| Kolehmainen, J | 1 |
| Priyadarshini, M | 1 |
| Toleikyte, G | 1 |
| Chen, YC | 3 |
| Panula, P | 1 |
| Kells, AP | 1 |
| Eberling, J | 2 |
| Su, X | 1 |
| Pivirotto, P | 2 |
| Bringas, J | 1 |
| Hadaczek, P | 1 |
| Narrow, WC | 1 |
| Bowers, WJ | 1 |
| Federoff, HJ | 1 |
| Forsayeth, J | 1 |
| Bankiewicz, KS | 3 |
| Zhang, ZT | 1 |
| Cao, XB | 1 |
| Xiong, N | 1 |
| Wang, HC | 1 |
| Huang, JS | 1 |
| Sun, SG | 1 |
| Wang, T | 3 |
| Ovsepian, LM | 1 |
| Kazarian, GS | 1 |
| Zakarian, AV | 1 |
| L'vov, MV | 1 |
| Melkonian, MM | 1 |
| Zakharian, GV | 1 |
| Akopdzhanian, AA | 1 |
| Chandran, K | 1 |
| Joseph, J | 1 |
| Antholine, WE | 1 |
| Hillard, CJ | 1 |
| Kanthasamy, A | 2 |
| Kalyanaraman, B | 1 |
| Steidinger, TU | 1 |
| Standaert, DG | 2 |
| Yacoubian, TA | 1 |
| Egawa, N | 1 |
| Yamamoto, K | 1 |
| Inoue, H | 2 |
| Hikawa, R | 1 |
| Nishi, K | 1 |
| Mori, K | 1 |
| Rieker, C | 1 |
| Engblom, D | 1 |
| Kreiner, G | 1 |
| Domanskyi, A | 1 |
| Schober, A | 3 |
| Stotz, S | 1 |
| Neumann, M | 2 |
| Yuan, X | 1 |
| Grummt, I | 1 |
| Schütz, G | 1 |
| Parlato, R | 1 |
| Jazwa, A | 1 |
| Rojo, AI | 1 |
| Innamorato, NG | 1 |
| Hesse, M | 1 |
| Cuadrado, A | 1 |
| Kim, JI | 1 |
| Yang, EJ | 1 |
| Lee, MS | 1 |
| Huh, Y | 1 |
| Cho, IH | 1 |
| Kang, S | 1 |
| Koh, HK | 1 |
| Goldberg, NR | 1 |
| Zimin, IA | 1 |
| Logvinov, IO | 1 |
| Antipova, TA | 1 |
| Kovalev, GI | 1 |
| Riahi, G | 1 |
| Parent, M | 1 |
| Pereira, MC | 1 |
| Secco, M | 1 |
| Suzuki, DE | 1 |
| Janjoppi, L | 1 |
| Rodini, CO | 1 |
| Torres, LB | 1 |
| Araújo, BH | 1 |
| Cavalheiro, EA | 1 |
| Zatz, M | 1 |
| Okamoto, OK | 1 |
| Conte-Perales, L | 1 |
| Barroso-Chinea, P | 3 |
| Gómez-Bautista, V | 1 |
| Roda, E | 1 |
| Ardashov, OV | 1 |
| Pavlova, AV | 1 |
| Il'ina, IV | 1 |
| Morozova, EA | 1 |
| Korchagina, DV | 1 |
| Karpova, EV | 1 |
| Volcho, KP | 1 |
| Tolstikova, TG | 1 |
| Salakhutdinov, NF | 1 |
| Chang, YL | 1 |
| Chen, SJ | 1 |
| Kao, CL | 1 |
| Hung, SC | 1 |
| Ding, DC | 1 |
| Yu, CC | 1 |
| Ku, HH | 1 |
| Lin, CP | 1 |
| Lee, KH | 1 |
| Wang, JJ | 1 |
| Chen, LK | 1 |
| Li, HY | 1 |
| Chiou, SH | 1 |
| Charron, G | 1 |
| Laux, A | 1 |
| Nosten-Bertrand, M | 1 |
| Giros, B | 1 |
| Delalande, F | 1 |
| Van Dorsselaer, A | 1 |
| Vital, A | 1 |
| Goumon, Y | 1 |
| Shchepinov, MS | 1 |
| Chou, VP | 1 |
| Pollock, E | 1 |
| Cantor, CR | 1 |
| Molinari, RJ | 1 |
| Manning-Boğ, AB | 1 |
| Xu, CL | 1 |
| Wang, QZ | 1 |
| Sun, LM | 1 |
| Li, XM | 1 |
| Deng, JM | 1 |
| Li, LF | 1 |
| Xu, R | 1 |
| Ma, SP | 1 |
| Chung, YC | 1 |
| Bok, E | 1 |
| Huh, SH | 1 |
| Yoon, SH | 1 |
| Kim, SR | 1 |
| Maeng, S | 1 |
| Park, SH | 1 |
| Jin, BK | 1 |
| Peng, S | 1 |
| Spetsieris, PG | 1 |
| Sossi, V | 1 |
| Eidelberg, D | 2 |
| Doudet, DJ | 4 |
| Anandhan, A | 1 |
| Tamilselvam, K | 1 |
| Radhiga, T | 1 |
| Rao, S | 1 |
| Tass, PA | 1 |
| Hauptmann, C | 1 |
| Boraud, T | 2 |
| Meissner, WG | 1 |
| Ghisoni, K | 1 |
| Latini, A | 1 |
| Quevedo, J | 1 |
| Dluzen, DE | 1 |
| Annese, V | 1 |
| Barcia, C | 4 |
| Ros-Bernal, F | 1 |
| Gómez, A | 1 |
| Ros, CM | 1 |
| De Pablos, V | 2 |
| De Stefano, ME | 1 |
| Mattson, MP | 2 |
| Selvaraj, S | 1 |
| Watt, JA | 1 |
| Lei, S | 1 |
| Birnbaumer, L | 1 |
| Singh, BB | 1 |
| Arraf, Z | 1 |
| Amit, T | 1 |
| Youdim, MB | 5 |
| Farah, R | 1 |
| Povarnina, PY | 1 |
| Gudasheva, TA | 1 |
| Vorontsova, ON | 1 |
| Bondarenko, NA | 1 |
| Seredenin, SB | 1 |
| Pattarini, R | 2 |
| Rong, Y | 1 |
| Shepherd, KR | 2 |
| Qu, C | 1 |
| Morgan, JI | 2 |
| Al-Sweidi, S | 1 |
| Suo, H | 1 |
| Liu, M | 1 |
| Cai, L | 1 |
| Xu, J | 1 |
| Zhu, C | 1 |
| Sheng, Z | 1 |
| Ju, MS | 1 |
| Ha, SK | 1 |
| Kim, SY | 1 |
| Yao, L | 1 |
| Li, W | 1 |
| She, H | 1 |
| Dou, J | 1 |
| Jia, L | 1 |
| He, Y | 1 |
| Yang, Q | 1 |
| Cápiro, NL | 1 |
| Walker, DI | 1 |
| Pennell, KD | 2 |
| Pang, Y | 1 |
| Han, Y | 1 |
| Mao, Z | 1 |
| Aguiar, AS | 1 |
| Villarinho, JG | 1 |
| Ferreira, J | 1 |
| Figueiredo, CP | 1 |
| Walz, R | 1 |
| Wu, DD | 1 |
| Huang, L | 1 |
| Li, YC | 1 |
| Feng, L | 1 |
| Chassain, C | 3 |
| Bielicki, G | 1 |
| Carcenac, C | 1 |
| Ronsin, AC | 1 |
| Renou, JP | 1 |
| Savasta, M | 1 |
| Durif, F | 3 |
| Pain, S | 1 |
| Gochard, A | 1 |
| Bodard, S | 1 |
| Gulhan, Z | 1 |
| Prunier-Aesch, C | 1 |
| Chalon, S | 1 |
| Ye, W | 1 |
| Bajpai, P | 1 |
| Sangar, MC | 1 |
| Tang, W | 1 |
| Bansal, S | 1 |
| Chowdhury, G | 1 |
| Cheng, Q | 1 |
| Fang, JK | 1 |
| Martin, MV | 1 |
| Guengerich, FP | 1 |
| Avadhani, NG | 1 |
| Breidert, T | 1 |
| Callebert, J | 2 |
| Heneka, MT | 1 |
| Landreth, G | 1 |
| Launay, JM | 2 |
| Schroeder, JA | 3 |
| Schneider, JS | 10 |
| Holden, JE | 3 |
| Jivan, S | 3 |
| Ruth, TJ | 2 |
| Heimer, G | 2 |
| Bar-Gad, I | 2 |
| Goldberg, JA | 2 |
| Bergman, H | 4 |
| Chen, XC | 1 |
| Zhu, YG | 1 |
| Fang, F | 1 |
| Chen, LM | 1 |
| Bolin, LM | 1 |
| Strycharska-Orczyk, I | 1 |
| Murray, R | 1 |
| Di Monte, D | 2 |
| Mandir, AS | 2 |
| Simbulan-Rosenthal, CM | 1 |
| Poitras, MF | 1 |
| Lumpkin, JR | 1 |
| Smulson, ME | 1 |
| Kupina, NC | 1 |
| Detloff, MR | 1 |
| Dutta, S | 1 |
| Hall, ED | 1 |
| Vieregge, P | 1 |
| Matsumura, M | 2 |
| Kojima, J | 1 |
| Ourednik, J | 1 |
| Ourednik, V | 1 |
| Lynch, WP | 1 |
| Schachner, M | 1 |
| Snyder, EY | 1 |
| Nandi, D | 1 |
| Aziz, TZ | 2 |
| Giladi, N | 1 |
| Winter, J | 1 |
| Stein, JF | 1 |
| Kurosaki, R | 2 |
| Muramatsu, Y | 3 |
| Michimata, M | 2 |
| Matsubara, M | 4 |
| Imai, Y | 5 |
| Itoyama, Y | 2 |
| Escola, L | 1 |
| Michelet, T | 1 |
| Douillard, G | 1 |
| Guehl, D | 1 |
| Bioulac, B | 6 |
| Burbaud, P | 1 |
| Duan, W | 1 |
| Ladenheim, B | 1 |
| Yu, QS | 1 |
| Oyler, J | 1 |
| Cutler, RG | 1 |
| Cadet, JL | 2 |
| Greig, NH | 1 |
| Steindler, DA | 1 |
| Yudin, AG | 1 |
| Kuznetsov, Y | 1 |
| Shul'govskii, VV | 1 |
| Oh, JD | 1 |
| Bibbiani, F | 2 |
| Chase, TN | 2 |
| Hansard, MJ | 2 |
| Smith, LA | 4 |
| Jackson, MJ | 6 |
| Cheetham, SC | 1 |
| Jenner, P | 9 |
| Ghorayeb, I | 1 |
| Stefanova, N | 2 |
| Wenning, GK | 2 |
| Tison, F | 2 |
| Henry, B | 3 |
| Hill, M | 1 |
| Crossman, A | 1 |
| Brotchie, J | 1 |
| Kuoppamäki, M | 2 |
| Al-Barghouthy, G | 1 |
| Jackson, M | 1 |
| Smith, L | 1 |
| Zeng, BY | 1 |
| Quinn, N | 1 |
| Willesen, MG | 1 |
| Gammeltoft, S | 1 |
| Vaudano, E | 1 |
| Maratos, EC | 2 |
| Pearce, RK | 3 |
| Cannizzaro, C | 1 |
| Korlipara, LV | 1 |
| Schapira, AH | 1 |
| Wade, TV | 2 |
| Teismann, P | 5 |
| Tieu, K | 5 |
| Cohen, O | 1 |
| Marks, D | 1 |
| Gross, CE | 9 |
| Jaber, M | 2 |
| Podell, M | 1 |
| Hadjiconstantinou, M | 1 |
| Smith, MA | 1 |
| Neff, NH | 1 |
| Eberhardt, O | 1 |
| Schulz, JB | 3 |
| Elder, CM | 2 |
| Okun, MS | 1 |
| Patrick, SK | 1 |
| Crocker, SJ | 2 |
| Liston, P | 1 |
| Anisman, H | 2 |
| Lee, CJ | 1 |
| Smith, PD | 2 |
| Earl, N | 1 |
| Thompson, CS | 1 |
| Park, DS | 2 |
| Korneluk, RG | 1 |
| Robertson, GS | 2 |
| Watanabe, H | 2 |
| Wu, YQ | 1 |
| Limburg, DC | 1 |
| Wilkinson, DE | 2 |
| Jackson, P | 1 |
| Steiner, JP | 2 |
| Hamilton, GS | 2 |
| Belyakov, SA | 1 |
| Ischiropoulos, H | 4 |
| Maratos, E | 1 |
| Meissner, W | 2 |
| Ramirez, AD | 1 |
| Menniti, FS | 1 |
| Tillerson, JL | 1 |
| Reverón, ME | 1 |
| Orth, M | 1 |
| Tabrizi, SJ | 1 |
| Cumming, P | 2 |
| Gillings, NM | 1 |
| Jensen, SB | 1 |
| Bjarkam, C | 1 |
| Gjedde, A | 1 |
| Muralikrishnan, D | 2 |
| Eschalier, A | 2 |
| Takahata, K | 2 |
| Shimazu, S | 2 |
| Yoneda, F | 2 |
| Ogawa, M | 1 |
| Iida, Y | 2 |
| Saji, H | 3 |
| Tamashiro, A | 1 |
| Parain, K | 2 |
| Hapdey, C | 1 |
| Rousselet, E | 2 |
| Marchand, V | 1 |
| Dumery, B | 1 |
| Tsang, F | 1 |
| Soong, TW | 1 |
| Thiffault, C | 1 |
| Di Monte, DA | 4 |
| Oiwa, Y | 3 |
| Eberling, JL | 1 |
| Nagy, D | 1 |
| Emborg, ME | 4 |
| Sedelis, M | 5 |
| Hofele, K | 4 |
| Schwarting, RK | 5 |
| Huston, JP | 5 |
| Belknap, JK | 1 |
| Sugama, S | 1 |
| Chirichigno, JW | 1 |
| Gregorio, J | 1 |
| Lorenzl, S | 1 |
| Shin, DH | 1 |
| Browne, SE | 2 |
| Shimizu, Y | 1 |
| Joh, TH | 1 |
| Albers, DS | 1 |
| Iravani, MM | 1 |
| Collier, TJ | 2 |
| Steece-Collier, K | 1 |
| Kordower, JH | 5 |
| Duty, S | 1 |
| Crossman, AR | 6 |
| Joubert, C | 1 |
| Orieux, G | 1 |
| Cohen-Salmon, C | 1 |
| Chuenkova, MV | 1 |
| Pereira, MA | 1 |
| Hill, MP | 1 |
| McGuire, SG | 1 |
| Michel, A | 1 |
| Grimée, R | 1 |
| Klitgaard, H | 1 |
| Belin, D | 1 |
| Duconger, S | 1 |
| Piazza, PV | 1 |
| Schwarzschild, MA | 3 |
| Xu, K | 3 |
| Oztas, E | 1 |
| Petzer, JP | 2 |
| Castagnoli, K | 3 |
| Chen, JF | 3 |
| Ren, J | 1 |
| Porter, JE | 1 |
| Wold, LE | 1 |
| Aberle, NS | 1 |
| Haselton, JR | 1 |
| Diguet, E | 1 |
| Gao, HM | 1 |
| Wilson, B | 1 |
| Ali, SF | 2 |
| Hong, JS | 2 |
| Liu, B | 3 |
| Kulak, JM | 1 |
| Furuya, T | 2 |
| Hayakawa, H | 2 |
| Yamada, M | 1 |
| Yoshimi, K | 2 |
| Hisahara, S | 1 |
| Miura, M | 2 |
| Mizuno, Y | 3 |
| Mochizuki, H | 3 |
| Hayley, S | 1 |
| Shree, T | 1 |
| Mount, M | 1 |
| Slack, R | 1 |
| Harnack, D | 1 |
| Benazzouz, A | 1 |
| Klivenyi, P | 2 |
| Calingasan, NY | 4 |
| Gardian, G | 2 |
| Bubber, P | 1 |
| Gibson, GE | 1 |
| Patel, MS | 1 |
| Betarbet, R | 2 |
| Poisik, O | 1 |
| Sherer, TB | 1 |
| Greenamyre, JT | 3 |
| Sánchez Bahillo, A | 1 |
| Bautista, V | 1 |
| Poza Y Poza, M | 1 |
| Fernández-Barreiro, A | 3 |
| Kenchappa, RS | 1 |
| Diwakar, L | 2 |
| Annepu, J | 2 |
| Ravindranath, V | 3 |
| Nicholson, SL | 1 |
| Benner, EJ | 1 |
| Mosley, RL | 1 |
| Destache, CJ | 1 |
| Lewis, TB | 1 |
| Gorantla, S | 1 |
| Nemachek, C | 1 |
| Green, SR | 1 |
| Frielingsdorf, H | 1 |
| Schwarz, K | 1 |
| Brundin, P | 1 |
| Mohapel, P | 1 |
| Lai, A | 1 |
| Sum, J | 1 |
| Xie, JX | 3 |
| Rowlands, DK | 2 |
| Gou, YL | 2 |
| Leung, CC | 1 |
| Chung, YW | 2 |
| Chan, HC | 2 |
| Liang, LP | 1 |
| Patel, M | 1 |
| Levitskaya, NG | 1 |
| Sebentsova, EA | 1 |
| Andreeva, LA | 1 |
| Alfeeva, LY | 1 |
| Kamenskii, AA | 1 |
| Myasoedov, NF | 1 |
| Bartoli, C | 1 |
| Dinucci, D | 1 |
| Takamatsu, H | 1 |
| Noda, A | 1 |
| Ichise, R | 1 |
| Iwashita, A | 1 |
| Mihara, K | 1 |
| Yamazaki, S | 1 |
| Matsuoka, N | 1 |
| Nishimura, S | 1 |
| Papa, SM | 2 |
| Auberson, YP | 1 |
| Dervan, AG | 1 |
| Beales, M | 1 |
| McBean, GJ | 1 |
| Totterdell, S | 2 |
| Snyder, AK | 1 |
| Meredith, GE | 3 |
| Sanchez-Pernaute, R | 2 |
| Guigoni, C | 2 |
| Håkansson, K | 1 |
| Barthe, N | 1 |
| Fisone, G | 1 |
| Monaca, C | 1 |
| Jacquesson, JM | 1 |
| Gelé, P | 1 |
| Maréchal, X | 1 |
| Derambure, P | 1 |
| Xu, BB | 1 |
| Liu, CQ | 1 |
| Gao, X | 1 |
| Zhang, WQ | 1 |
| Wang, SW | 1 |
| Cao, YL | 1 |
| Cleren, C | 2 |
| Dung Ling, Z | 1 |
| Carvey, PM | 1 |
| Fletcher-Turner, A | 1 |
| Yurek, DM | 1 |
| Sladek, JR | 1 |
| Andrews, ZB | 1 |
| Horvath, B | 1 |
| Barnstable, CJ | 1 |
| Elsworth, J | 1 |
| Elseworth, J | 1 |
| Roth, RH | 1 |
| Matthews, RT | 1 |
| Horvath, TL | 1 |
| Mandel, S | 4 |
| Maor, G | 1 |
| Leng, A | 1 |
| Mura, A | 1 |
| Feldon, J | 1 |
| Kurkowska-Jastrzebska, I | 2 |
| Bałkowiec-Iskra, E | 1 |
| Joniec, I | 1 |
| Litwin, T | 1 |
| Członkowski, A | 2 |
| Członkowska, A | 2 |
| Costantini, LC | 1 |
| Patel, R | 1 |
| Braga, R | 1 |
| Kouzmine, I | 1 |
| Canteras, NS | 4 |
| Da Cunha, C | 5 |
| Schlüter, OM | 1 |
| Lenzi, P | 1 |
| Gesi, M | 1 |
| Ruffoli, R | 1 |
| Lazzeri, G | 2 |
| Pontarelli, F | 1 |
| Pellegrini, A | 1 |
| Ruggieri, S | 2 |
| Paparelli, A | 2 |
| Südhof, TC | 1 |
| Faherty, CJ | 1 |
| Raviie Shepherd, K | 1 |
| Herasimtschuk, A | 1 |
| Gennuso, F | 1 |
| Desole, S | 1 |
| Barden, N | 1 |
| Morale, MC | 1 |
| Holmer, HK | 1 |
| Keyghobadi, M | 1 |
| Menashe, RA | 1 |
| Shen, YQ | 1 |
| Hebert, G | 2 |
| Su, Y | 1 |
| Moze, E | 1 |
| Neveu, PJ | 1 |
| Li, KS | 1 |
| Mingam, R | 1 |
| Arsaut, J | 1 |
| Dantzer, R | 1 |
| Demotes-Mainard, J | 1 |
| Lau, YS | 2 |
| Novikova, L | 1 |
| Roels, C | 1 |
| Ferro, MM | 2 |
| Bellissimo, MI | 1 |
| Anselmo-Franci, JA | 1 |
| Angellucci, ME | 1 |
| Haobam, R | 1 |
| Sindhu, KM | 1 |
| Chandra, G | 1 |
| Zhu, WW | 1 |
| Liu, ZL | 1 |
| Xu, HW | 1 |
| Chu, WZ | 1 |
| Ye, QY | 1 |
| Xie, AM | 1 |
| Li, JR | 1 |
| Nathans, J | 1 |
| Hadj Tahar, A | 4 |
| Rouillard, C | 1 |
| Cuadrado-Tejedor, M | 1 |
| Sesma, MT | 1 |
| Giménez-Amaya, JM | 1 |
| Ortiz, L | 1 |
| Pennathur, S | 1 |
| Perier, C | 1 |
| Vonsattel, JP | 1 |
| Heinecke, JW | 1 |
| Ostergren, A | 1 |
| Fredriksson, A | 2 |
| Brittebo, EB | 1 |
| Silva, RM | 1 |
| Ries, V | 1 |
| Oo, TF | 1 |
| Yarygina, O | 1 |
| Ryu, EJ | 1 |
| Lu, PD | 1 |
| Marciniak, SJ | 1 |
| Ron, D | 1 |
| Kholodilov, N | 1 |
| Burke, RE | 1 |
| Bassilana, F | 1 |
| Mace, N | 1 |
| Stutzmann, JM | 1 |
| Pradier, L | 2 |
| Benavides, J | 1 |
| Ménager, J | 1 |
| Bautista-Hernández, V | 1 |
| Sánchez-Bahillo, A | 1 |
| Bernal, I | 1 |
| Martín, J | 1 |
| Bañón, R | 1 |
| Ulanowska, K | 1 |
| Piosik, J | 1 |
| Gwizdek-Wiśniewska, A | 1 |
| We Grzyn, G | 1 |
| Heise, CE | 1 |
| Teo, ZC | 1 |
| Wallace, BA | 2 |
| Ashkan, K | 2 |
| Bélanger, N | 2 |
| Yamaguchi, H | 1 |
| Kajitani, K | 1 |
| Dan, Y | 1 |
| Furuichi, M | 1 |
| Ohno, M | 1 |
| Sakumi, K | 1 |
| Kang, D | 1 |
| Nakabeppu, Y | 1 |
| Kaneda, K | 1 |
| Tachibana, Y | 1 |
| Imanishi, M | 1 |
| Kita, H | 1 |
| Shigemoto, R | 1 |
| Takada, M | 2 |
| Soares, J | 1 |
| Rosa-Neto, P | 1 |
| Munk, OL | 1 |
| McCallum, SE | 1 |
| Parameswaran, N | 2 |
| Bao, S | 1 |
| Grady, SR | 1 |
| Fukumitsu, N | 1 |
| Suzuki, M | 1 |
| Fukuda, T | 1 |
| Kiyono, Y | 1 |
| Kajiyama, S | 1 |
| Oida, Y | 2 |
| Kitaichi, K | 1 |
| Nakayama, H | 1 |
| Ito, Y | 1 |
| Fujimoto, Y | 1 |
| Shimazawa, M | 2 |
| Nagai, H | 1 |
| Hara, H | 3 |
| Liang, Y | 1 |
| Li, S | 1 |
| Zou, Q | 1 |
| Su, B | 1 |
| Meuer, K | 2 |
| Pitzer, C | 1 |
| Krüger, C | 1 |
| Göricke, B | 1 |
| Laage, R | 1 |
| Lingor, P | 1 |
| Peters, K | 1 |
| Schlachetzki, JC | 1 |
| Kobayashi, K | 1 |
| Dietz, GP | 1 |
| Weber, D | 1 |
| Schäbitz, WR | 1 |
| Bach, A | 1 |
| Bähr, M | 2 |
| Schneider, A | 1 |
| Weishaupt, JH | 2 |
| Ohashi, S | 1 |
| Mori, A | 1 |
| Kurihara, N | 1 |
| Nakai, M | 1 |
| Nakajima, K | 1 |
| Minematsu, M | 1 |
| Teng, X | 1 |
| Sakai, T | 1 |
| Sakai, R | 2 |
| Kaji, R | 1 |
| Fukui, K | 1 |
| Chalimoniuk, M | 1 |
| Lukacova, N | 1 |
| Marsala, J | 1 |
| Langfort, J | 1 |
| Kaur, D | 1 |
| Peng, J | 1 |
| Chinta, SJ | 1 |
| Rajagopalan, S | 1 |
| Andersen, JK | 1 |
| Moirano, J | 1 |
| Schafernak, KT | 1 |
| Moirano, M | 1 |
| Evans, M | 1 |
| Konecny, T | 1 |
| Roitberg, B | 2 |
| Ambarish, P | 1 |
| Mangubat, E | 1 |
| Holden, J | 1 |
| Leestma, JE | 1 |
| Ren, YR | 2 |
| Nishida, Y | 1 |
| Yasuda, T | 2 |
| Jishage, K | 1 |
| Uchihara, T | 1 |
| Yokota, T | 1 |
| Nakai, K | 1 |
| Itakura, T | 1 |
| Hasbani, DM | 1 |
| O'Malley, KL | 1 |
| Okuda, K | 1 |
| Kotake, Y | 1 |
| Ohta, S | 1 |
| Kang, UJ | 1 |
| Rivlin-Etzion, M | 2 |
| Haber, SN | 2 |
| Batista, LC | 1 |
| Medeiros, R | 1 |
| Pandolfo, P | 1 |
| Florio, JC | 1 |
| Takahashi, RN | 3 |
| von Bohlen und Halbach, O | 1 |
| Hertel, R | 1 |
| Unsicker, K | 2 |
| van Vliet, SA | 2 |
| Vanwersch, RA | 2 |
| Jongsma, MJ | 2 |
| van der Gugten, J | 1 |
| Olivier, B | 2 |
| Dhanasekaran, M | 1 |
| Uthayathas, S | 1 |
| Karuppagounder, SS | 1 |
| Parameshwaran, K | 1 |
| Suppiramaniam, V | 1 |
| Ebadi, M | 1 |
| Brown-Borg, HM | 1 |
| Burton, NC | 1 |
| Kensler, TW | 1 |
| Guilarte, TR | 1 |
| Gomez-Ramirez, J | 2 |
| Johnston, TH | 3 |
| Pires, D | 1 |
| Voon, V | 2 |
| Gomez-Gallego, M | 1 |
| Bandettini Di Poggio, A | 1 |
| Soldani, P | 1 |
| De Blasi, A | 1 |
| Peterziel, H | 1 |
| von Bartheld, CS | 1 |
| Simon, H | 1 |
| Krieglstein, K | 1 |
| Lee, PH | 1 |
| Pang, H | 1 |
| Wie, MB | 1 |
| Kim, WK | 1 |
| Huang, WH | 1 |
| Kim, HC | 1 |
| Anderson, DW | 2 |
| Bradbury, KA | 1 |
| Pollo, C | 1 |
| Brard, PY | 1 |
| Fagret, D | 1 |
| Wietzikoski, S | 1 |
| Wietzikoski, EC | 1 |
| Silva, MH | 1 |
| Chandler, J | 1 |
| Andreatini, R | 2 |
| Cox, H | 2 |
| Togasaki, DM | 2 |
| von Coelln, R | 1 |
| Trinkaus, DB | 1 |
| Farah, MH | 1 |
| Leong Lim, K | 1 |
| Flint Beal, M | 1 |
| Liebetanz, D | 1 |
| Baier, PC | 1 |
| Paulus, W | 1 |
| Kong, H | 1 |
| Shi, X | 1 |
| Sun, X | 1 |
| Ding, J | 1 |
| Dridi, M | 1 |
| Meltzer, LT | 1 |
| Karunakaran, S | 1 |
| Saeed, U | 1 |
| Agarwal, V | 1 |
| Ramakrishnan, S | 1 |
| Iyengar, S | 1 |
| Katzenschlager, R | 1 |
| Rose, S | 1 |
| Stockwell, K | 1 |
| Tayarani-Binazir, KA | 1 |
| Zubair, M | 1 |
| Lees, AJ | 1 |
| Chefer, SI | 1 |
| Kimes, AS | 1 |
| Matochik, JA | 1 |
| Horti, AG | 1 |
| Kurian, V | 1 |
| Shumway, D | 1 |
| London, ED | 1 |
| Mukhin, AG | 1 |
| San Sebastián, W | 1 |
| Guillén, J | 1 |
| Manrique, M | 1 |
| Belzunegui, S | 1 |
| Ciordia, E | 1 |
| Izal-Azcárate, A | 1 |
| Garrido-Gil, P | 1 |
| Sawada, H | 1 |
| Hishida, R | 1 |
| Hirata, Y | 1 |
| Ono, K | 1 |
| Suzuki, H | 1 |
| Muramatsu, S | 1 |
| Nakano, I | 1 |
| Nagatsu, T | 1 |
| Sawada, M | 1 |
| Milioli, EM | 1 |
| Cologni, P | 1 |
| Santos, CC | 1 |
| Marcos, TD | 1 |
| Yunes, VM | 1 |
| Fernandes, MS | 1 |
| Schoenfelder, T | 1 |
| Costa-Campos, L | 1 |
| Irie, Y | 1 |
| Murata, T | 1 |
| Ishige, A | 1 |
| Anjiki, N | 1 |
| Watanabe, K | 1 |
| Quinn, LP | 1 |
| Perren, MJ | 1 |
| Brackenborough, KT | 1 |
| Woodhams, PL | 1 |
| Vidgeon-Hart, M | 1 |
| Chapman, H | 1 |
| Pangalos, MN | 1 |
| Upton, N | 1 |
| Virley, DJ | 1 |
| Hamill, CE | 1 |
| Richardson, JR | 1 |
| Yuan, H | 1 |
| Greene, JG | 1 |
| Tripanichkul, W | 1 |
| Sripanichkulchai, K | 1 |
| Duce, JA | 1 |
| Maeda, J | 1 |
| Inaji, M | 1 |
| Okauchi, T | 1 |
| Obayashi, S | 1 |
| Higuchi, M | 1 |
| Suhara, T | 1 |
| Tanioka, Y | 1 |
| Boyd, JD | 1 |
| Jang, H | 1 |
| Faherty, C | 1 |
| Slack, S | 1 |
| Kataoka, A | 1 |
| Hua-Qin, W | 1 |
| Masuda, M | 1 |
| Ikeda, T | 1 |
| Tsukita, K | 1 |
| Soda, M | 1 |
| Kodama, T | 1 |
| Fuwa, T | 1 |
| Honda, Y | 1 |
| Kaneko, S | 1 |
| Matsumoto, S | 1 |
| Wakamatsu, K | 1 |
| Ito, S | 1 |
| Aosaki, T | 1 |
| Itohara, S | 1 |
| Kanamatsu, T | 1 |
| Otsuki, T | 1 |
| Tokuno, H | 1 |
| Okamoto, K | 1 |
| Umeda, M | 2 |
| Tsukada, Y | 1 |
| Tsang, LL | 1 |
| Ho, LS | 1 |
| O'Leary, K | 1 |
| Oizumi, H | 1 |
| Hayashita-Kinoh, H | 1 |
| Arai, H | 1 |
| Seki, T | 1 |
| Lorenzo, B | 1 |
| Schomer, A | 1 |
| Sireci, A | 1 |
| Wille, EJ | 1 |
| Sgadò, P | 1 |
| Liu, LX | 1 |
| Chen, WF | 1 |
| Wong, MS | 1 |
| van Vlieta, SA | 1 |
| Blezer, EL | 1 |
| Blesa, FJ | 1 |
| Alvarez-Erviti, L | 1 |
| Guridi, J | 2 |
| Marmor, O | 1 |
| Saban, G | 1 |
| Rosin, B | 1 |
| Vaadia, E | 2 |
| Prut, Y | 1 |
| Takagi, S | 1 |
| Watanabe, Y | 1 |
| Luk'yanova, LD | 1 |
| Storozheva, ZI | 1 |
| Proshin, AT | 1 |
| Goetze, O | 1 |
| Woitalla, D | 1 |
| Kadoguchi, N | 2 |
| Hahn, PJ | 1 |
| Miocinovic, S | 1 |
| McIntyre, CC | 1 |
| Miller, RL | 1 |
| James-Kracke, M | 1 |
| Sun, GY | 1 |
| Sun, AY | 1 |
| Orsi, A | 1 |
| Howson, PA | 1 |
| Dixon, K | 1 |
| Callizot, N | 1 |
| Rees, DD | 1 |
| Nicholas, AP | 1 |
| Lubin, FD | 1 |
| Vattem, P | 1 |
| Sweatt, JD | 1 |
| Kohutnicka, M | 1 |
| Cummins, A | 1 |
| Oyagi, A | 1 |
| Izuta, H | 1 |
| Matsunaga, N | 1 |
| Adachi, T | 1 |
| Desimone, R | 1 |
| Fiorani, M | 1 |
| Oldfield, EH | 1 |
| Decamp, E | 1 |
| Wade, T | 1 |
| Goulet, M | 4 |
| Madras, BK | 1 |
| Vukosavic, S | 2 |
| Neystat, M | 1 |
| Jakowec, M | 2 |
| Grünblatt, E | 3 |
| Lewandowska, E | 1 |
| Lechowicz, W | 1 |
| Pope-Coleman, A | 1 |
| Tinker, JP | 1 |
| Auburger, GW | 3 |
| Morgan, S | 3 |
| Police, S | 1 |
| Costa, S | 1 |
| Marsden, CD | 1 |
| Ramos, E | 1 |
| Linazasoro, G | 1 |
| Agani, FH | 1 |
| Pichiule, P | 1 |
| Chavez, JC | 1 |
| LaManna, JC | 1 |
| Davies, L | 1 |
| Stein, J | 1 |
| France, S | 1 |
| McGeer, E | 1 |
| Wyatt, RJ | 1 |
| Blanchet, PJ | 3 |
| Doucet, JP | 1 |
| Nestler, E | 1 |
| Ma, SY | 1 |
| Chu, Y | 2 |
| Leventhal, L | 1 |
| McBride, J | 1 |
| Chen, EY | 1 |
| Palfi, S | 1 |
| Roitberg, BZ | 1 |
| Brown, WD | 1 |
| Pyzalski, R | 1 |
| Taylor, MD | 1 |
| Carvey, P | 1 |
| Ling, Z | 1 |
| Trono, D | 1 |
| Hantraye, P | 1 |
| Déglon, N | 1 |
| Aebischer, P | 1 |
| Raz, A | 1 |
| Gassen, M | 1 |
| Gross, A | 1 |
| Kitamura, Y | 1 |
| Shimohama, S | 1 |
| Akaike, A | 1 |
| Taniguchi, T | 1 |
| Ekesbo, A | 1 |
| Bangassoro, E | 1 |
| Svensson, KA | 1 |
| Tedroff, J | 1 |
| Schmidt, N | 1 |
| Shin, P | 1 |
| Sramek, JG | 1 |
| Stebbins, GT | 1 |
| Hamilton, JS | 1 |
| Suzdak, PD | 1 |
| Youdim, M | 1 |
| Chen, Q | 1 |
| Giasson, BI | 1 |
| Djaldatti, R | 1 |
| Souza, JM | 1 |
| Lee, VM | 1 |
| Shimoke, K | 2 |
| Chiba, H | 1 |
| Pérez, V | 1 |
| Morón, J | 1 |
| Pastó, M | 1 |
| Unzeta, M | 1 |
| Naini, AB | 1 |
| Petzinger, G | 1 |
| Miller, R | 1 |
| Akram, M | 1 |
| Zarate-Lagunes, M | 1 |
| Gu, WJ | 1 |
| Blanchard, V | 1 |
| Muriel, MP | 1 |
| Mouatt-Prigent, A | 1 |
| Bonici, B | 1 |
| Parent, A | 1 |
| Yelnik, J | 1 |
| Boehme, GA | 1 |
| Moussaoui, S | 1 |
| Faucheux, B | 1 |
| Raisman-Vozari, R | 1 |
| Agid, Y | 1 |
| Brice, A | 1 |
| Steyn, SJ | 1 |
| Steyn, S | 1 |
| Lavertu, N | 1 |
| Lemieux, AM | 1 |
| Smeyne, M | 2 |
| Goloubeva, O | 1 |
| Danysz, W | 1 |
| Quack, G | 1 |
| Archer, T | 1 |
| Staal, R | 1 |
| Xu, YH | 2 |
| Beilstein, M | 1 |
| Sonsalla, PK | 2 |
| Rathke-Hartlieb, S | 1 |
| Kahle, PJ | 1 |
| Ozmen, L | 1 |
| Haid, S | 1 |
| Okochi, M | 1 |
| Haass, C | 1 |
| Marcotte, ER | 1 |
| Chugh, A | 1 |
| Barlas, C | 1 |
| Mishra, RK | 1 |
| Neavin, T | 1 |
| Fonck, C | 1 |
| Baudry, M | 1 |
| Gevaerd, MS | 2 |
| Miyoshi, E | 1 |
| Silveira, R | 2 |
| Staal, RG | 1 |
| Yang, JM | 1 |
| Hait, WN | 1 |
| Rothblat, DS | 1 |
| Tanaka, K | 2 |
| Petroske, E | 1 |
| Callen, S | 1 |
| Hille, CJ | 1 |
| Maneuf, YP | 1 |
| Kumagai, T | 1 |
| Chen, JY | 1 |
| Hsu, PC | 1 |
| Hsu, IL | 1 |
| Yeh, GC | 1 |
| Kupsch, A | 1 |
| Sautter, J | 1 |
| Götz, ME | 1 |
| Breithaupt, W | 1 |
| Schwarz, J | 1 |
| Riederer, P | 1 |
| Gerlach, M | 1 |
| Morgan, WW | 1 |
| Nelson, JF | 1 |
| Ishiwata, K | 1 |
| Koyanagi, Y | 1 |
| Kawamura, K | 1 |
| Toda, J | 1 |
| Senda, M | 1 |
| Sano, T | 1 |
| Nakahara, T | 1 |
| Yamamoto, T | 1 |
| Endo, K | 1 |
| Kayama, H | 1 |
| Yee, RE | 1 |
| Irwin, I | 1 |
| Milonas, C | 1 |
| Stout, DB | 1 |
| Huang, SC | 1 |
| Shoghi-Jadid, K | 1 |
| Satyamurthy, N | 1 |
| Delanney, LE | 1 |
| Farahani, KF | 1 |
| Delfani, K | 1 |
| Janson, AM | 1 |
| Phelps, ME | 1 |
| Barrio, JR | 1 |
| Ghribi, O | 1 |
| Genc, S | 1 |
| Akhisaroglu, M | 1 |
| Kuralay, F | 1 |
| Genc, K | 1 |
| Vadseth, C | 1 |
| Kudo, M | 1 |
| Takatsu, H | 1 |
| Wada, H | 1 |
| Maekawa, N | 1 |
| Takemura, M | 1 |
| Saito, K | 1 |
| Fujiwara, H | 1 |
| Ikeda, K | 1 |
| Kurokawa, M | 1 |
| Aoyama, S | 1 |
| Kuwana, Y | 1 |
| Wei, L | 1 |
| Wu, Y | 1 |
| Soni, R | 1 |
| Scott, C | 1 |
| Ross, DT | 1 |
| Howorth, P | 1 |
| Valentine, H | 1 |
| Liang, S | 1 |
| Spicer, D | 1 |
| Fuller, M | 1 |
| Steiner, J | 1 |
| Obata, T | 1 |
| Chera, B | 1 |
| Schaecher, KE | 1 |
| Rocchini, A | 1 |
| Imam, SZ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Trial for Near Infrared Endoventricular Illumination for Neuroprotection in Very Early Cases of Parkinson's Disease (Ev-NIRT)[NCT04261569] | 14 participants (Anticipated) | Interventional | 2020-12-14 | Recruiting | |||
| Role of Sleep Homeostasis in the Development of the L-Dopa Induced Dyskinesias in Patients With Parkinson's Disease[NCT02200887] | 48 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease[NCT03639064] | Phase 2 | 15 participants (Anticipated) | Interventional | 2020-12-01 | Recruiting | ||
| Subthalamic Nucleus (STN) and Globus Pallidus Internus (GPi) Deep Brain Stimulation (DBS) in Patients With Primary Dystonia（RELAX Study）[NCT03017586] | 72 participants (Actual) | Interventional | 2017-12-27 | Completed | |||
| Evaluation of 5-[123I]-A-85380 and SPECT Imaging as a Marker of Nicotinic Receptor Density in the Brain of Parkinson Disease Subjects[NCT00397696] | Phase 2 | 9 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Leukine (Sargramostim) for Parkinson's Disease[NCT01882010] | Phase 1 | 37 participants (Actual) | Interventional | 2013-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
28 reviews available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Parkinsonian Disorders
| Article | Year |
|---|---|
Experimental models of chemically induced Parkinson's disease in zebrafish at the embryonic larval stage: a systematic review.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Larva; Models | 2023 |
Parkinson's disease, aging and adult neurogenesis: Wnt/β-catenin signalling as the key to unlock the mystery of endogenous brain repair.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Astrocytes; Dopaminergic Neurons; Huma | 2020 |
How Parkinsonian toxins dysregulate the autophagy machinery.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Autophagy; Humans; Methamphetamine; Mitophagy; MPTP Po | 2013 |
The MPTP Story.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Hist | 2017 |
alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain; Disease Models, Anima | 2010 |
[Pathophysiology of Parkinson's disease: an update].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomedical Research; Disease Models, Animal; | 2010 |
Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Estrogens; Gonadal Steroid Hormones; Humans; | 2012 |
[Pesticide exposure and Parkinson's syndrome - the epidemiological and experimental evidence].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aryl Hydrocarbon Hydroxylases; Basal Ganglia; Case-Con | 2002 |
Experimental parkinsonism in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Apomorphine; Basal Ganglia | 2001 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Mitochondria; Nitric Oxide; Oxidative | 2002 |
Pathogenic role of glial cells in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Astrocytes; Dopamine Agent | 2003 |
Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspases; Cell Cycle; Inflammation | 2003 |
Models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cells, Cultured; Disease Models, A | 2003 |
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Disease Models, Animal; Dopamine A | 2003 |
Interactions between environmental and genetic factors in the pathophysiology of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Progression; Dopamine; Environ | 2003 |
Nitric oxide and reactive oxygen species in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Mice; Nitric Oxide; Nitric Oxide Synt | 2003 |
The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agonists; Dr | 2003 |
Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A1 Receptor Antagonists; Adenosine A2 Recept | 2003 |
Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental parkinsonism: pivotal role for glia-neuron interactions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dose-Response Relationship, Drug; Gene Expres | 2005 |
Behavioral models of Parkinson's disease in rodents: a new look at an old problem.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Motor Activity; Motor Neurons; Motor | 2006 |
The role of MPTP in Parkinson's disease: connecting brain and gut?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Enteric Nervou | 2008 |
Oxidative and inflammatory pathways in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Herbicides; Humans; Inflammation; Lipopolysac | 2009 |
Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Apomorphine; Chelating Agents; | 2000 |
The parkinsonian models: invertebrates to mammals.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Genetically Modified; Apoptosis; Cel | 2000 |
The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Laboratory; Medical Laboratory Perso | 2001 |
Molecular neurotoxicological models of Parkinsonism: focus on genetic manipulation of mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Humans; Methamphetamine; Mic | 2001 |
Behavioral phenotyping of the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Dopamine; | 2001 |
Environmental estrogen-like chemicals and hydroxyl radicals induced by MPTP in the striatum: a review.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Environmental Pollutants; Es | 2002 |
503 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Parkinsonian Disorders
| Article | Year |
|---|---|
Additive effects of mGluR
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Bridg | 2021 |
Magnetothermal nanoparticle technology alleviates parkinsonian-like symptoms in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Deep Brain Stimulation; Dis | 2021 |
Neuroprotective effect of paeoniflorin in the mouse model of Parkinson's disease through α-synuclein/protein kinase C δ subtype signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Annexin A5; Anti-Inflammator | 2021 |
Discovery of Resorcinol-Based Polycyclic Structures as Tyrosinase Inhibitors for Treatment of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Mice; Mice, Inbred C5 | 2022 |
Atractylon, a novel dopamine 2 receptor agonist, ameliorates Parkinsonian like motor dysfunctions in MPTP-induced mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2022 |
Cerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cerebral Cortex; Corpus Striatum; Dopamine; H | 2022 |
Preventative effects of 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives (
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Mice; Mice, Inbred C57BL; MPTP Poison | 2022 |
COVID-19 Infection Enhances Susceptibility to Oxidative Stress-Induced Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; COVID-19; Disease Models, Animal; Dopamine; H | 2022 |
Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amidohydrolases; Animals; Disease Models, Animal; Dopa | 2022 |
Inhibiting von Hippel‒Lindau protein-mediated Dishevelled ubiquitination protects against experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; beta Catenin; Caenorhabditis elegans; Disease | 2023 |
Gastric Enteric Glial Cells: A New Contributor to the Synucleinopathies in the MPTP-Induced Parkinsonism Mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Mice | 2022 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
Whether the Subacute MPTP-Treated Mouse is as Suitable as a Classic Model of Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2023 |
Novel FABP3 ligand, HY-11-9, ameliorates neuropathological deficits in MPTP-induced Parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Dopa | 2023 |
Whole Transcriptome Analysis of Substantia Nigra in Mice with MPTP-Induced Parkinsonism Bearing Defective Glucocerebrosidase Activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gene Expression Profi | 2023 |
A primate nigrostriatal atlas of neuronal vulnerability and resilience in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Neuroprotection and immunomodulation of progesterone in the gut of a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain-Derived Neurotrophic Factor; Dis | 2020 |
Effects of sleep disruption on stress, nigrostriatal markers, and behavior in a chronic/progressive MPTP male mouse model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Corticosterone; Disease Mode | 2019 |
Serotonergic innervation of the striatum in a nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intravenous; Animals; Corpus Striatum; | 2020 |
Experimental study of antiparkinsonian action of the harmine hydrochloride original compound.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catalepsy; Haloperidol; | 2019 |
Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious precl
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Callithrix; Corpus S | 2020 |
Motor Neurons Pathology After Chronic Exposure to MPTP in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Male; Mice; Mice, Inbred C57BL; Motor Neurons | 2020 |
Acupuncture Inhibits the Increase in Alpha-Synuclein in Substantia Nigra in an MPTP- Induced Parkinsonism Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; alpha-Synuclein; Animals; Disease | 2020 |
Embelin averts MPTP-induced dysfunction in mitochondrial bioenergetics and biogenesis via activation of SIRT1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzoquinones; Cell Death; Cell Line; Energy | 2020 |
Parkinsonism Differently Affects the Single Neuronal Activity in the Primary and Supplementary Motor Areas in Monkeys: An Investigation in Linear and Nonlinear Domains.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Brain Waves; Female; Linea | 2020 |
Anti-neuroinflammatory effects of dimethylaminomylide (DMAMCL, i.e., ACT001) are associated with attenuating the NLRP3 inflammasome in MPTP-induced Parkinson disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Catalase; Circadian Rhythm; | 2020 |
Gait Deficits and Loss of Striatal Tyrosine Hydroxlase/Trk-B are Restored Following 7,8-Dihydroxyflavone Treatment in a Progressive MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Flav | 2020 |
Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; | 2020 |
Eupatilin prevents behavioral deficits and dopaminergic neuron degeneration in a Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Astrocytes; Behavior, Animal; Dopa | 2020 |
Knockdown of microglial Cav2.2 N-type voltage-dependent Ca
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calcium Channels, L-Type; Calcium Channels, N | 2020 |
Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior | 2020 |
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior | 2020 |
miR-132-5p regulates apoptosis and autophagy in MPTP model of Parkinson's disease by targeting ULK1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antagomirs; Apoptosis; Autophagy; Autophagy-R | 2020 |
Preparation and Neuroprotective Activity of Glucuronomannan Oligosaccharides in an MPTP-Induced Parkinson's Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apoptosis; Apoptosis Re | 2020 |
Effect of Anti-Glutamate Antibodies in Modeled Parkinsonian Syndrome.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Antibodies; Antip | 2020 |
Pepper component 7-ethoxy-4-methylcoumarin, a novel dopamine D2 receptor agonist, ameliorates experimental Parkinson's disease in mice and Caenorhabditis elegans.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Genetically Modified; Behavior, Anim | 2021 |
Alkaloids extracted from Uncaria rhynchophylla demonstrate neuroprotective effects in MPTP-induced experimental parkinsonism by regulating the PI3K/Akt/mTOR signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkaloids; Animals; Dopamine; Drugs, Chinese Herbal; M | 2021 |
Cortical Projection From the Premotor or Primary Motor Cortex to the Subthalamic Nucleus in Intact and Parkinsonian Adult Macaque Monkeys: A Pilot Tracing Study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Macaca fascicularis; Motor Cortex; Neural Pat | 2020 |
Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Catec | 2021 |
L-DOPA regulates α-synuclein accumulation in experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain; Dopamine Agents; Fema | 2021 |
D
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Bromocriptine; C | 2021 |
Atorvastatin improves motor function, anxiety and depression by NOX2-mediated autophagy and oxidative stress in MPTP-lesioned mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Atorvastatin; Autophagy; Behavior, A | 2020 |
MPTP toxicity causes vocal, auditory, orientation and movement defects in the echolocation bat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Aromatic-L-Amino-Acid Decarboxylas | 2021 |
Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Corpus Striatum; Dose-Respon | 2021 |
Comparative Ultrastructural Analysis of Thalamocortical Innervation of the Primary Motor Cortex and Supplementary Motor Area in Control and MPTP-Treated Parkinsonian Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Female; Macaca mulatta; Male; Motor Cortex; N | 2021 |
Inhibition of long non-coding RNA HOXA11-AS against neuroinflammation in Parkinson's disease model via targeting miR-124-3p mediated FSTL1/NF-κB axis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Disease Models, Animal; Dopaminerg | 2021 |
A New Tool to Study Parkinsonism in the Context of Aging: MPTP Intoxication in a Natural Model of Multimorbidity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2021 |
A Pilot Study of Changes in the Level of Catecholamines and the Activity of α-2-Macroglobulin in the Tear Fluid of Patients with Parkinson's Disease and Parkinsonian Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Area Under Curve; Biomarkers; Case-Control St | 2021 |
Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2021 |
Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson's Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; alpha-Synuclein; Animals; Apopto | 2021 |
Retinal Degeneration Following Chronic Administration of the Parkinsonism-Inducing Neurotoxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Mice; Neurotoxins; Parkinsonian Dis | 2021 |
microRNA-106b-containing extracellular vesicles affect autophagy of neurons by regulating CDKN2B in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Autophagy; Cells, Cultured; Cyclin | 2021 |
GSK-3 mediates nuclear translocation of p62/SQSTM1 in MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cell Nucleus; Disease Models, Anim | 2021 |
Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; CD8 Antigens; CD8-Positive T-Lymphocyt | 2021 |
Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Arabidopsis Proteins; C | 2017 |
Changes in blood anti-oxidation enzyme levels in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Glutathione Peroxidase; Glutathione Transfera | 2017 |
Structural and Functional State of Erythrocyte Membranes in Mice at Different Stages of Experimental Parkinson's Disease Induced by Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholinesterase; Animals; Erythrocyte Membrane; K | 2017 |
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astroc | 2017 |
The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Cation | 2017 |
Potential repositioning of exemestane as a neuroprotective agent for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Androstadienes; Animals; Antineoplastic Agents; Antipa | 2017 |
GPR55: A therapeutic target for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2017 |
[The effect of neurotoxin MPTP administration to mice on the proteomic profile of brain isatin-binding proteins].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Carrier Proteins; Disease Models, Anim | 2017 |
Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Chemistry; Disease Mo | 2017 |
Role of ethanolic extract of Bacopa monnieri against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced mice model via inhibition of apoptotic pathways of dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Bacopa; Disease Models, Animal; Do | 2017 |
Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Diffusion Tensor Imaging; Disease Mode | 2018 |
TREM2 overexpression attenuates neuroinflammation and protects dopaminergic neurons in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adenoviridae; Animals; | 2018 |
Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Disease Mode | 2018 |
Long non-coding RNA NEAT1 mediates the toxic of Parkinson's disease induced by MPTP/MPP+ via regulation of gene expression.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; | 2018 |
NMDA receptor blockade ameliorates abnormalities of spike firing of subthalamic nucleus neurons in a parkinsonian nonhuman primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2-Amino-5-phosphonovalerate; Action Potentials; Animal | 2018 |
The Nurr1 Ligand,1,1-bis(3'-Indolyl)-1-(
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Active Transport, Cell Nucleus; Animals; Brain; Cell C | 2018 |
Telmisartan Ameliorates Astroglial and Dopaminergic Functions in a Mouse Model of Chronic Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiotensin II Type 1 Receptor Blockers; Animals; Astr | 2018 |
Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2018 |
A non-human primate model for stable chronic Parkinson's disease induced by MPTP administration based on individual behavioral quantification.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Disease Models, Anim | 2019 |
Mitigation Effects of a Novel Herbal Medicine, Hepad, on Neuroinflammation, Neuroapoptosis, and Neuro-Oxidation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Apoptosis; Cell Line; C | 2018 |
Effect of NAC treatment and physical activity on neuroinflammation in subchronic Parkinsonism; is physical activity essential?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcysteine; Analysis of Variance; Animals; Calcium | 2018 |
Counteracting neuroinflammation in experimental Parkinson's disease favors recovery of function: effects of Er-NPCs administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Coculture Techniques; Corpus Striatum; Cytoki | 2018 |
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Glycogen Synthase Kin | 2019 |
Aquaporin-4 deficiency reduces TGF-β1 in mouse midbrains and exacerbates pathology in experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Aquaporin 4; Astrocytes; Cel | 2019 |
Cordycepin mitigates MPTP-induced Parkinson's disease through inhibiting TLR/NF-κB signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Line, Tumor; Deoxyadenosines; Lipopolysa | 2019 |
A simple method to study motor and non-motor behaviors in adult zebrafish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Behavioral Research; Diseas | 2019 |
Rosmarinic acid attenuates inflammatory responses through inhibiting HMGB1/TLR4/NF-κB signaling pathway in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Behavior, Animal; C | 2019 |
Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson's disease mouse model: Endothelial and microglial effects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcarnitine; Animals; Astrocytes; Dopamine Plasma | 2019 |
Acupuncture Inhibits the Increase in Alpha-Synuclein by Modulating SGK1 in an MPTP Induced Parkinsonism Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; alpha-Synuclein; Animals; Chronic | 2019 |
Anti-inflammatory Activity of Ursolic Acid in MPTP-Induced Parkinsonian Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antiparkinson Agent | 2019 |
Non-cell autonomous modulation of tyrosine hydroxylase by HMGB1 released from astrocytes in an acute MPTP-induced Parkinsonian mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; HMGB1 Protein; Male; Mice; Mice, | 2019 |
Impairment of Nrf2- and Nitrergic-Mediated Gastrointestinal Motility in an MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; | 2019 |
Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dependovirus; Drug Eval | 2019 |
Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Corpus Striatum; Dopamine; Homova | 2013 |
Neuronal loss in the caudal intralaminar thalamic nuclei in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholinesterase; Animals; Apoptosis; Calbindin 1; | 2014 |
Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Analysis of Variance; Anim | 2013 |
The effect of dopamine on MPTP-induced rotarod disability.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Levo | 2013 |
Microtubule alterations occur early in experimental parkinsonism and the microtubule stabilizer epothilone D is neuroprotective.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Axonal Transport; Blotting, Western; Dopamine | 2013 |
Estradiol and brain serotonin reuptake transporter in long-term ovariectomized parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Citalopram; Estradiol; Female; Macaca | 2013 |
Gait disorders in parkinsonian monkeys with pedunculopontine nucleus lesions: a tale of two systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Count; Cholinergic Neu | 2013 |
Alterations in energy metabolism, neuroprotection and visual signal transduction in the retina of Parkinsonian, MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electron Transport; Electrophoresis, Gel, Two | 2013 |
L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor | 2014 |
Effects of the root bark of Paeonia suffruticosa on mitochondria-mediated neuroprotection in an MPTP-induced model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Disease | 2014 |
Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Corpus S | 2014 |
Alteration of daily and circadian rhythms following dopamine depletion in MPTP treated non-human primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Circadian Rhythm; Dopamine; Female; Intracell | 2014 |
Substantial telomere shortening in the substantia nigra of telomerase-deficient mice does not increase susceptibility to MPTP-induced dopamine depletion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2014 |
Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Count; Central Nervous System Age | 2014 |
Measuring attention in a Parkinson's disease rat model using the 5-arm maze test.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Attention; Cues; Male; Maze Learning; Motor A | 2014 |
Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; CA1 Region, Hipp | 2014 |
Anti-Parkinson effects of a selective alpha2C-adrenoceptor antagonist in the MPTP marmoset model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Adrenergic alpha-2 Receptor Anta | 2014 |
In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Chromatography, High Pressure Liq | 2014 |
Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechol O-Methyltransf | 2014 |
Protection of dopamine neurons by vibration training and up-regulation of brain-derived neurotrophic factor in a MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Dopamine; | 2014 |
Protective effects of salidroside in the MPTP/MPP(+)-induced model of Parkinson's disease through ROS-NO-related mitochondrion pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Survival; Dose-Response Relationship, Dr | 2015 |
Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chromosomes, Artificial, Ba | 2014 |
Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carboxylic Acids; Disease M | 2014 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; | 2015 |
Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8,11,14-Eicosatrienoic Acid; Adamantane; Animals; Beha | 2015 |
Fractalkine over expression suppresses α-synuclein-mediated neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antigen Presentation; Astroc | 2015 |
Attenuation of neuroinflammatory responses and behavioral deficits by Ligusticum officinale (Makino) Kitag in stimulated microglia and MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Behavior, Animal; C | 2015 |
L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dyskinesia, | 2014 |
The effect of different doses of near infrared light on dopaminergic cell survival and gliosis in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Caudate Nucleus; Cell Count; Cell | 2016 |
Vinpocetine attenuates MPTP-induced motor deficit and biochemical abnormalities in Wistar rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Cyclic AMP; Cyclic GMP; Ence | 2015 |
Possible role of GABA-B receptor modulation in MPTP induced Parkinson's disease in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Baclofen; Cerebral Cortex; Corpus Striatum; C | 2015 |
MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Ag | 2015 |
Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopaminergic Neurons; D | 2015 |
Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Abietanes; Animals; Anti-Inflammatory Agents; Ants; Ce | 2015 |
Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Benzeneacetamides; Disease | 2015 |
Apoptotic Mediators are Upregulated in the Skeletal Muscle of Chronic/Progressive Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Apoptosis Regulatory Proteins; Cas | 2015 |
Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Catalepsy; Corpus Striatum; En | 2015 |
MPTP-induced parkinsonism in mice alters striatal and nigral xCT expression but is unaffected by the genetic loss of xCT.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amino Acid Transport S | 2015 |
Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Cells, Cultured; Cerebral C | 2015 |
Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease | 2015 |
Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2015 |
Neuroprotective effects of Eucommia ulmoides Oliv. and its bioactive constituent work via ameliorating the ubiquitin-proteasome system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Cell Line | 2015 |
Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/β-catenin dependent pathways in a mice model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals | 2015 |
Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease.
Topics: 1-Deoxynojirimycin; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Count; Cells, | 2015 |
Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Basal Ganglia; Catalepsy; Disease | 2015 |
Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Caspase 3; Disease Mode | 2015 |
Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopaminergic Neurons; Limoni | 2015 |
MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting α-synuclein expression in MPTP-induced Parkinson's disease mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cell Line, Tumor; Down-Regul | 2015 |
Primary motor cortex of the parkinsonian monkey: altered encoding of active movement.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Corpus Striatum; Female; M | 2016 |
Mechanism of Nanotization-Mediated Improvement in the Efficacy of Caffeine Against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Active Transport, Cell Nucleus; Animals; Biological Tr | 2015 |
Early Changes in Saccadic Eye Movement in Hemiparkinsonian MPTP-Treated Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Frontal Lobe; Macaca mulatta | 2015 |
α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti | 2015 |
Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Anti-Inflammatory Agents; Di | 2016 |
Individual and Familial Susceptibility to MPTP in a Common Marmoset Model for Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Corpus Striatum; Disease Models, | 2016 |
7,8-dihydroxyflavone protects 6-OHDA and MPTP induced dopaminergic neurons degeneration through activation of TrkB in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopaminergic Neurons; Flavo | 2016 |
Aging-related 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurochemial and behavioral deficits and redox dysfunction: improvement by AK-7.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Behavior Rating Scale; Benzamides; Cor | 2016 |
Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antigens, CD; Cell Line, Transformed; Disease | 2016 |
Effects of a higher dose of near-infrared light on clinical signs and neuroprotection in a monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2016 |
Effects of high-frequency stimulation of the internal pallidal segment on neuronal activity in the thalamus in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Deep Brain Stimulation; Di | 2016 |
Continuous MPTP intoxication in the Göttingen minipig results in chronic parkinsonian deficits.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Diseas | 2016 |
Proteomic Analysis of the Effect of Korean Red Ginseng in the Striatum of a Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blotting, Western; Corpus Striatum; Disease M | 2016 |
Rho kinase II interference by small hairpin RNA ameliorates 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine‑induced parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Biomarkers; Disease Models, | 2016 |
The behavioural and neuroprotective outcomes when 670nm and 810nm near infrared light are applied together in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2017 |
Chronic mild stress augments MPTP induced neurotoxicity in a murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Pharmaceutic; Animals; Body Weight; Brain-D | 2017 |
Effect of MPTP on Serotonergic Neuronal Systems and Mitochondrial Complex I Activity in the Living Brain: A PET Study on Conscious Rhesus Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopaminergic Neurons; Electron Transpo | 2017 |
Expression of Cbl-interacting protein of 85 kDa in MPTP mouse model of Parkinson's disease and 1-methyl-4-phenyl-pyridinium ion-treated dopaminergic SH-SY5Y cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Adaptor Proteins, Signal | 2008 |
Development of a stable, early stage unilateral model of Parkinson's disease in middle-aged rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Animals; Disease Models, Animal; Drug Adm | 2008 |
Amiloride is neuroprotective in an MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acid Sensing Ion Channels; Acidosis, Lactic; Amiloride | 2008 |
Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson's-like disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Central Nervous System; Disease Models, Anima | 2008 |
The tert-butoxyl radical mediated hydrogen atom transfer reactions of the Parkinsonian proneurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and selected tertiary amines.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amines; Carbon; Catalysis; Deuterium; Humans; Hydrogen | 2008 |
Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Pharmaceutic; Animals; Brain; Chromatograph | 2008 |
Deep brain stimulation reduces neuronal entropy in the MPTP-primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Deep Brain Stimulation; Di | 2008 |
Differential effects of the dopamine neurotoxin MPTP in animals with a partial deletion of the GDNF receptor, GFR alpha1, gene.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Count; Cell Survival; Disease Mod | 2008 |
Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Benza | 2008 |
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antip | 2008 |
Enhanced susceptibility to MPTP neurotoxicity in magnesium-deficient C57BL/6N mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Causality; Corpus Striatum; Disease Models, A | 2009 |
Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Analysis of Variance; Animals; Cell Death; Corp | 2008 |
Extranigral neurodegeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Calpain; Cell Line; Dipeptides; Hu | 2008 |
Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the HALLWAY task.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Behavioral Sciences; Biomec | 2009 |
Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Enteric Nervous Syste | 2009 |
The neurophysiology and effect of deep brain stimulation in a patient with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Corpus Striatum; Deep Brain Stimulation; Dopami | 2009 |
Effect of estradiol on striatal dopamine activity of female hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Biogenic Amines; Chromatogra | 2009 |
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix | 2009 |
Protective effect against Parkinson's disease-related insults through the activation of XBP1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcysteine; Animals; | 2009 |
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disea | 2009 |
MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 2009 |
Pyrethroid and organophosphate insecticide exposure in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease: an immunohistochemical analysis of tyrosine hydroxylase and glial fibrillary acidic protein in dorsolateral striatu
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chlorpyrifos; Disease Models, Animal; Drug Co | 2009 |
The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Blood-Brain Barrier; Br | 2009 |
Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caffeine; Corpus Striatum; Cytochrome P-450 C | 2009 |
Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholine; Aging; Animals; Axons; Cell Death; Dise | 2009 |
JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anthracenes; Cell Death; Cyclooxygenase 2; Di | 2009 |
Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cyclooxygenase 2; Disease Models, Animal; DNA | 2009 |
Elevated interleukin-1beta induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine aggravating dopaminergic neurodegeneration in old male mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Aging; Animals; Biomarkers; Cytokines; Di | 2009 |
Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Corpus Str | 2009 |
Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Cell Count; Cerebral | 2009 |
Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Ascorbic Acid; Brain; Central Nervous System | 2009 |
Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomechanical Phenomena; Chromatography, High | 2010 |
Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cell Membrane; Dyskines | 2010 |
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Cell Survival; Disease Models, Animal; | 2009 |
Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzamides; Brain; Disease Models, Animal; En | 2010 |
Gene expression profile of acupuncture treatment in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Animals; Biomarkers; Databases, G | 2010 |
Neuroprotective effects of bee venom pharmaceutical acupuncture in acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Acute Disease; Animals; Bee Venom | 2010 |
Vulnerability of peripheral catecholaminergic neurons to MPTP is not regulated by alpha-synuclein.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; | 2010 |
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Death; Cycloheximi | 2010 |
Exercise protects against MPTP-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytoprotection; Disease Models, Animal; Femal | 2010 |
Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cerebral Cortex; Corpus | 2010 |
Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catalepsy; Cell Death; Dopamine; Genetic Ther | 2010 |
Detection of MPTP-induced substantia nigra hyperechogenicity in Rhesus monkeys by transcranial ultrasound.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Female; Humans; Macac | 2010 |
Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Castration; Disease Models, Animal; Drug Tole | 2010 |
Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Dose- | 2010 |
Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2009 |
MPTP treatment increases expression of pre-pro-nociceptin/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Gene Expression Regulation; Male; Mice; Mice, | 2010 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease M | 2010 |
Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; C | 2010 |
Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Bezafibrat | 2010 |
VTA neurons show a potentially protective transcriptional response to MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytoprotection; Disease Models, Animal; Gene | 2010 |
Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2010 |
Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding, Competitive; Biological Transport, A | 2010 |
Objective and quantitative evaluation of motor function in a monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Mapping; Carbon Radioisotopes; C | 2010 |
Microglial activation and age-related dopaminergic neurodegeneration in MPTP-treated SAMP8 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Brain; CD11b Antigen; Cell Count; Corp | 2010 |
Dopaminergic cell damage and vulnerability to MPTP in Pink1 knockdown zebrafish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gene Knockdown Techni | 2010 |
Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Brain; Chromatography, | 2010 |
Morin exerts neuroprotective actions in Parkinson disease models in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Ag | 2010 |
[Oxidative processes and lipid metabolism in the experimental induced Parkinsonian syndrome].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Lipid Metabolism; Lip | 2010 |
Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cells, Cultured; Cytoprotection; Disease Mode | 2010 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease M | 2010 |
A neuroprotective role for angiogenin in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cell Line, Tumor; Cytoprotection; | 2011 |
The endoplasmic reticulum stress sensor, ATF6α, protects against neurotoxin-induced dopaminergic neuronal death.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Activating Transcription Factor 6; Animals; Cell Death | 2011 |
Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of rapamycin signaling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Nucleolus; Dopamine; Gene Deletio | 2011 |
Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticarcinogenic Agents; Antioxidants; Basal | 2011 |
Bee venom reduces neuroinflammation in the MPTP-induced model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bee | 2011 |
Effect of intermittent washout periods on progressive lesioning of the nigrostriatal pathway with 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dise | 2011 |
[A comparative study of hemantane and amantadine effects on dopamine transporter expression in brain of normal and MPTP-treated C57BL/6 mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Amantadine; Animals; Antiparkinson Agents; | 2011 |
Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Bioge | 2011 |
Contamination of mesenchymal stem-cells with fibroblasts accelerates neurodegeneration in an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopaminergic Neurons; Fibroblasts; Hum | 2011 |
Pallidothalamic-projecting neurons in Macaca fascicularis co-express GABAergic and glutamatergic markers as seen in control, MPTP-treated and dyskinetic monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Colorimetry; DNA Primers; Dopamine; Dyskinesi | 2011 |
Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclohexanols; Disease | 2011 |
Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripotent stem cells and inhibits teratoma formation in rats with Parkinson-like pathology.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cells, Cultured; Docosahexaenoic A | 2012 |
Endogenous morphine-like compound immunoreactivity increases in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; alpha-Methyltyrosine; Analysis of Variance; Anim | 2011 |
Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Linolenic Acid; | 2011 |
Asiaticoside: attenuation of neurotoxicity induced by MPTP in a rat model of Parkinsonism via maintaining redox balance and up-regulating the ratio of Bcl-2/Bax.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; bcl-2-Associated X Protein; Cor | 2012 |
Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzoxazines; Cells, Cultured; Coculture Tech | 2011 |
Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Fema | 2012 |
Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biflavonoids; Catechin; Dopaminergic Neurons; | 2012 |
The translational value of the MPTP non-human primate model of Parkinsonism for deep brain stimulation research.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Deep Brain Stimulation; Disease Models, Anima | 2011 |
Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Age Factors; Animals; Anim | 2012 |
Evidence of oligodendrogliosis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2013 |
Parkinson's disease: don't mess with calcium.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calcium Signaling; Dopaminergic Neurons; Endo | 2012 |
Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Calcium Channels; Calcium Si | 2012 |
Lithium and oxidative stress lessons from the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopaminergic Neurons; Lithiu | 2012 |
Antiparkinsonian properties of a nerve growth factor dipeptide mimetic GK-2 in in vivo experiments.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catalepsy; Dipeptides; | 2011 |
Long-lasting transcriptional refractoriness triggered by a single exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Female; Mice; Mice, Inbred C | 2012 |
Effect of oestrogen receptors on brain NMDA receptors of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; CA1 Region, Hippocampal; Dose-Response | 2012 |
NRSF/REST neuronal deficient mice are more vulnerable to the neurotoxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Genetic Predisposition to Disease; Mice; Mice | 2013 |
Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Dopamine; Dopaminergic Neuro | 2012 |
Acacetin protects dopaminergic cells against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuroinflammation in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Dopaminergic Neuron | 2012 |
Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Behav | 2012 |
Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Agmatine; Analysis of Vari | 2012 |
LLDT-67 attenuates MPTP-induced neurotoxicity in mice by up-regulating NGF expression.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Astrocytes; Cells, Cultured | 2012 |
Does MPTP intoxication in mice induce metabolite changes in the nucleus accumbens? A ¹H nuclear MRS study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Magnetic Resonance Spectroscopy; Male; Mice; | 2013 |
Who else was intoxicated with MPTP in Santa Clara?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; California; History, 20th Century; History, 21st Centu | 2012 |
Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Dopa | 2013 |
Acetylcholinesterase deficiency decreases apoptosis in dopaminergic neurons in the neurotoxin model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcholinesterase; Alk | 2013 |
Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Cell Line; Cyto | 2013 |
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; | 2002 |
GABA-opioid interactions in the globus pallidus: [D-Ala2]-Met-enkephalinamide attenuates potassium-evoked GABA release after nigrostriatal lesion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cats; Disease Models, Anima | 2002 |
GABA(A) and mu-opioid receptor binding in the globus pallidus and endopeduncular nucleus of animals symptomatic for and recovered from experimental Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Cats; Entopeduncular Nucleus | 2002 |
In vivo receptor assay with multiple ligand concentrations: an equilibrium approach.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Kinetics; Ligands; Macaca mulatta; Male; Mode | 2002 |
Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antiparkinson Agents; Brom | 2002 |
Protective effect of ginsenoside Rg1 against MPTP-induced apoptosis in mouse substantia nigra neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Ginsen | 2002 |
Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Corpus Striatum; Disease Models, | 2002 |
A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; DNA; Electrophoretic | 2002 |
Neuroimmunophilin ligand V-10,367 is neuroprotective after 24-hour delayed administration in a mouse model of diffuse traumatic brain injury.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Body Weight; Brain Inju | 2002 |
The role of the pedunculopontine tegmental nucleus in experimental parkinsonism in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Afferent Pathways; Animals; Basal Ganglia; Brain Stem; | 2001 |
Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Cell Count; Cell Survival; Dextroamphe | 2002 |
Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bicuculline; Cholinergic Fibers; Female; GABA | 2002 |
Role of nitric oxide synthase against MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; C | 2002 |
Disruption of the proprioceptive mapping in the medial wall of parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Dopamine Agents; Electrophysio | 2002 |
p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Behavi | 2002 |
Neural stem cells, scaffolds, and chaperones.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biocompatible Materials; Cell Survival; Dextr | 2002 |
Disturbances of saccadic eye movements in monkeys during development of MPTP-induced syndrome.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Macaca; Parkinsonian Disorders; Reaction Time | 2002 |
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Diben | 2002 |
Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Uptake Inhibitors; Animals; Callithrix; Dop | 2002 |
Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Diseas | 2002 |
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Callithrix | 2002 |
Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dose-Resp | 2002 |
Activation of the c-Jun N terminal kinase pathway in an animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; JNK | 2002 |
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, | 2003 |
Experimental parkinsonism is associated with increased pallidal GAD gene expression and is reversed by site-directed antisense gene therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Female; Genetic Therapy; Globus Pallidus; Glu | 2003 |
Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Binding, Competitive; C | 2003 |
Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Brain; Cats; Choline; Corpus S | 2003 |
Stimulation of the subthalamic nucleus changes the firing pattern of pallidal neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Behavior, Animal; Disease | 2003 |
Attenuation of MPTP-induced neurotoxicity and behavioural impairment in NSE-XIAP transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Death; Dopamine; Drug | 2003 |
Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biomarkers; Dopamine; Down-Regula | 2003 |
Neuroprotective effects of inhibitors of dipeptidyl peptidase-iV in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Dipeptidyl Peptidase 4; Mice; Mot | 2003 |
NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Base Sequence; Disease Models, Animal; DNA Pr | 2003 |
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; | 2003 |
Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Corpus Striatum; Disease Model | 2003 |
Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dose-Respon | 2003 |
Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2003 |
Kinetics of the uptake and distribution of the dopamine D(2,3) agonist (R)-N-[1-(11)C]n-propylnorapomorphine in brain of healthy and MPTP-treated Göttingen miniature pigs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Brain; Carbon Radioisotopes; Kin | 2003 |
D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Dose-R | 2003 |
Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disea | 2003 |
Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Cell Death; Clorgyline; Disease | 2003 |
Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Ditiocarb; Dopamine; | 2003 |
Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Male; Mice; Mice, Inbred C57BL; Neu | 2003 |
Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2003 |
Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Carotid Arteries; Cor | 2003 |
Chromosomal loci influencing the susceptibility to the parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bayes Theorem; Chromosome Mapping; Chromosome | 2003 |
Minocycline enhances MPTP toxicity to dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Dose-R | 2003 |
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2003 |
Primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Corpus Striatum; Disease Models, Anima | 2003 |
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Antiparkinson Agents | 2003 |
Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Monoamines; Corpus Striatum; Male; M | 2003 |
PDNF, a human parasite-derived mimic of neurotrophic factors, prevents caspase activation, free radical formation, and death of dopaminergic cells exposed to the Parkinsonism-inducing neurotoxin MPP+.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Caspase 3; Caspa | 2003 |
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Antiparkinson Agents; Callit | 2003 |
Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Central Nervous System Stimulants | 2003 |
Depressed contractile function and adrenergic responsiveness of cardiac myocytes in an experimental model of Parkinson disease, the MPTP-treated mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Caffeine; Calcium; Cell Size; | 2004 |
Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Clinical Trials as Topic; Corpus | 2004 |
Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Cells, Cultured; Coculture Tech | 2004 |
Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptation, Physiological; alpha7 Nicotinic Acetylchol | 2004 |
Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspase Inhibitors; Caspases; Casp | 2004 |
Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Animals; Cell Death; Corpus Striatum; Di | 2004 |
Deep brain stimulation for Parkinson's disease: potential risk of tissue damage associated with external stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electric Stimulation; | 2004 |
Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Cell Count; Cerebral Cortex; | 2004 |
Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cyclic AMP-Dependent Protein Kinases; Disease | 2004 |
Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biomarkers; Calbindins; Corpus St | 2004 |
Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Electron Transport | 2004 |
Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzopyrans; Brain; Callithrix; Disease Model | 2004 |
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adoptive Transfer; Animals; Coat Protein Complex I; Co | 2004 |
No evidence for new dopaminergic neurons in the adult mammalian substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromodeoxyuridine; Cell Movement; Dopamine; M | 2004 |
Selective recovery of striatal 125I-alpha-conotoxinmii nicotinic receptors after nigrostriatal damage in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Azetidines; Bridged Bicyclo Compounds, Hetero | 2004 |
Neuroprotective effects of Bak Foong Pill in 1-methyl-4-phenyl-1,2,3,6-tetrahyrdropyridine (MPTP)-induced Parkinson's disease model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Base Sequence; Disease Models, Animal; DNA Pr | 2004 |
Iron-sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aconitate Hydratase; Age Factors; Animals; Blotting, W | 2004 |
The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenocorticotropic Hormone; Animals; Anxiety; Disease | 2004 |
Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Disease Models, Animal; Dopami | 2004 |
Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allyl Compounds; Anima | 2004 |
An application of a new planar positron imaging system (PPIS) in a small animal: MPTP-induced parkinsonism in mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Brain; Disease Models, Animal; | 2004 |
Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disab | 2004 |
Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biological Transport; Cell Count; | 2004 |
Mapping dopamine function in primates using pharmacologic magnetic resonance imaging.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Brain; Brain Mapping; Cerebrovas | 2004 |
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 2005 |
Vigilance states in a parkinsonian model, the MPTP mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arousal; Circadian Rhythm; Disease Models, An | 2004 |
Striatal preprotachykinin gene expression reflects parkinsonian signs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cats; Corpus Striatum; Dise | 2004 |
Possible mechanisms of the protection of ginsenoside Re against MPTP-induced apoptosis in substantia nigra neurons of Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Caspas | 2005 |
Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Corpus Striatum; Disease Models, Anima | 2004 |
Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Brain-Derived Neurotrophic Factor; Dis | 2005 |
Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Survival; C | 2005 |
Chronic implantation of deep brain stimulation leads in animal models of neurological disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Brain; Brain Mapping; Deep | 2005 |
Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Apomorphine; Catechin; Disea | 2004 |
Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chronic Disease; Corpus Striatum; Cytoprotect | 2005 |
Immunization with myelin oligodendrocyte glycoprotein and complete Freund adjuvant partially protects dopaminergic neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage in mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Corpus | 2005 |
Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Disease Mo | 2005 |
Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cognition Disorders; Denervation; Disease Mod | 2005 |
Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Male; Mice; Mice, Inbred C57 | 2005 |
Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Brain-Derived Neurotrop | 2005 |
Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caloric Restriction; Corpus Striatum; Disease | 2005 |
In mice, production of plasma IL-1 and IL-6 in response to MPTP is related to behavioral lateralization.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Corpus | 2005 |
Cellular distribution of interleukin-1alpha-immunoreactivity after MPTP intoxication in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biomarkers; Corpus Striatum; Dise | 2005 |
MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Apoptosis; Bl | 2005 |
Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Analysis of Variance; Animals; Brai | 2005 |
Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Mo | 2005 |
[Effect of the oil from ganoderma lucidum spores on pathological changes in the substantia nigra and behaviors of MPTP-treated mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Drugs, Chinese Her | 2005 |
Written in our genes?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Sequence; Animals; Cell Death; Dopamine; Hu | 2005 |
Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; B | 2005 |
Changes in cytoskeletal gene expression linked to MPTP-treatment in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Cyclic AMP; Cytoskeletal Pro | 2005 |
Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amyotrophic Lateral Sclerosis; Animals; Brain; Corpus | 2005 |
Norharman-induced motoric impairment in mice: neurodegeneration and glial activation in substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Carbolines; Caspase 3; Caspases; D | 2006 |
CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Apoptosis; Axotomy; Behavio | 2005 |
Unraveling substantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Disease Models, Animal; Dise | 2005 |
Increased plasma levels of TNF-alpha but not of IL1-beta in MPTP-treated monkeys one year after the MPTP administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Interleukin-1; Macaca fascicularis; | 2005 |
Formation of stacking complexes between caffeine (1,2,3-trimethylxanthine) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine may attenuate biological effects of this neurotoxin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caffeine; Calorimetry; Humans; Models, Molecu | 2005 |
Cell survival patterns in the pedunculopontine tegmental nucleus of methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys and 6OHDA-lesioned rats: evidence for differences to idiopathic Parkinson disease patients?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Survival; Disease Mode | 2005 |
DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dehydroepiandrosterone; | 2006 |
MTH1, an oxidized purine nucleoside triphosphatase, protects the dopamine neurons from oxidative damage in nucleic acids caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; DNA | 2006 |
Down-regulation of metabotropic glutamate receptor 1alpha in globus pallidus and substantia nigra of parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Behavior, Animal; Benzoate | 2005 |
Neuronal firing before and after burst discharges in the monkey basal ganglia is predictably patterned in the normal state and altered in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Algorithms; Animals; Basal Ganglia; | 2006 |
Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Caudate Nucleus; Corpus Striatum; Domi | 2006 |
Compensation in pre-synaptic dopaminergic function following nigrostriatal damage in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Female; Male; Neur | 2006 |
Reduced 125I-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3-Iodobenzylguanidine; Animals; Dose-Response Relation | 2006 |
Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2006 |
Potential neuroprotective effect of low dose whole-body gamma-irradiation against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic toxicity in C57 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Gamma Rays; Male; Mice; Mice, Inbre | 2006 |
Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Nor | 2006 |
Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Aging; Animals; Brain; Cell Death; Corpus | 2006 |
Ameliorating effect of dimethylsulfoniopropionate on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease of mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Dopamine; Injections, Intrap | 2006 |
Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Apoptotic Protease-Activating Fact | 2006 |
Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Count; Cyclic GMP; | 2006 |
Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Age Factors; Aging; Animals; Ani | 2007 |
Basal ganglia lesions after MPTP administration in rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Female; Genetic Therapy; Glial | 2006 |
Genetic vitamin E deficiency does not affect MPTP susceptibility in the mouse brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Brain; Corpus Striatum; | 2006 |
Histological effects of intraputaminal infusion of glial cell line-derived neurotrophic factor in Parkinson disease model macaque monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Survival; Corpus Striatum; Dopamine; Fem | 2006 |
Wld(S) mice are protected against the Parkinsonian mimetic MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Blotting, Western; Brai | 2006 |
Parkinsonism-preventing activity of 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives in C57BL mouse in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Dopamine; Dopami | 2006 |
Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine primate model of Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antiparkinson Agents; Biol | 2006 |
The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Behavior, Animal; | 2006 |
MPTP treatment impairs tyrosine hydroxylase immunopositive fibers not only in the striatum, but also in the amygdala.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amygdala; Animals; Axons; Corpus Striatum; Disease Mod | 2005 |
A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Clinical Trials as Topi | 2006 |
Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Arousal; Benzhydryl Com | 2006 |
Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; C | 2007 |
Ebselen effects on MPTP-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Azoles; Brain; Cell Line, Tumor | 2006 |
In vivo modulation of the Parkinsonian phenotype by Nrf2.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antineoplastic Agents; Autoradiography; Cocai | 2006 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine | 2006 |
Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dopamine | 2006 |
Changes in the neuronal activity in the pedunculopontine nucleus in chronic MPTP-treated primates: an in situ hybridization study of cytochrome oxidase subunit I, choline acetyl transferase and substance P mRNA expression.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholine; Animals; Biomarkers; Choline O-Acetyltr | 2007 |
Convergent roles of alpha-synuclein, DA metabolism, and the ubiquitin-proteasome system in nigrostriatal toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Dopamine; Dopamine Agents; D | 2006 |
GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antibodies; Corpus Striatum; Glial Cell Line- | 2007 |
3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Astrocytes; Behavio | 2006 |
Neuroprotection in Parkinson models varies with toxin administration protocol.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antigens, Nuclear; Axons; Benzothiazoles; Bio | 2006 |
SPECT imaging, immunohistochemical and behavioural correlations in the primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Disea | 2007 |
Pre-training to find a hidden platform in the Morris water maze can compensate for a deficit to find a cued platform in a rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptation, Physiological; Analysis of Variance; Anima | 2007 |
Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Survival; Chemokines; Corpus Stri | 2007 |
The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl | 2007 |
MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzylamines; Catecholamines; Cell Survival; | 2007 |
A highly sensitive automated complex running wheel test to detect latent motor deficits in the mouse MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diagnosis, Computer-Assisted; Diagnostic Tech | 2007 |
Hypersensitivity of aquaporin 4-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine and astrocytic modulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aquaporin 4; Dose-Response Relationship, Drug | 2008 |
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Female; Macaca fascicularis; O | 2008 |
Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcysteine; Alkynes; Animals; Antioxidants; Antipa | 2007 |
Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; B | 2007 |
Protocol for the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Model | 2007 |
Estimation of D2-like receptor occupancy by dopamine in the putamen of hemiparkinsonian Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Kine | 2008 |
Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Carotid Body; Cell Count; Cell Di | 2007 |
Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Animal | 2007 |
Effect of acute administration of hydroalcohol extract of Ilex paraguariensis St Hilaire (Aquifoliaceae) in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Hydroxyl Radical; Ile | 2007 |
Toki-to protects dopaminergic neurons in the substantia nigra from neurotoxicity of MPTP in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine; Drugs, Chinese He | 2007 |
A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Corpus Striatum; Dopamine; Dose-Respon | 2007 |
Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Factor Xa; | 2007 |
17Beta-estradiol reduces nitrotyrosine immunoreactivity and increases SOD1 and SOD2 immunoreactivity in nigral neurons in male mice following MPTP insult.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Cell Count; Estradiol; Male; Mice | 2007 |
Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; B | 2008 |
Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cyclooxygenase 2; Disease Models, Animal; Dru | 2007 |
Pael receptor is involved in dopamine metabolism in the nigrostriatal system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2007 |
Changes in the rates of the tricarboxylic acid (TCA) cycle and glutamine synthesis in the monkey brain with hemiparkinsonism induced by intracarotid infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): studies by non-invasive 13C-magnetic reso
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Brain; Carbon Isotopes; Citric | 2007 |
Bak Foong protects dopaminergic neurons against MPTP-induced neurotoxicity by its anti-apoptotic activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Corpus Striatum; Dopamine; Dopamin | 2008 |
Paraquat: the red herring of Parkinson's disease research.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Humans; Molecu | 2007 |
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Circadian Rhythm; Dyskinesia, Drug-Induced; L | 2007 |
Alteration in the differentiation-related molecular expression in the subventricular zone in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Biomarkers; Caspases; Caspases | 2008 |
Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animal Feed; Animals; Coenzymes; Disease Models, Anima | 2008 |
CYP 2E1 mutant mice are resistant to DDC-induced enhancement of MPTP toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cricetinae; Cytochrome P-450 CYP2E1; Cytochro | 2007 |
Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2008 |
Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Benzhydryl Compounds; Biomarke | 2008 |
Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesia, Drug-Induced; Functional Laterali | 2008 |
Low-pass filter properties of basal ganglia cortical muscle loops in the normal and MPTP primate model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Behavior, Animal; Brain Ma | 2008 |
Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Cytoprotectio | 2008 |
Corrective effect of flavonoid-containing preparation Extralife on the development of Parkinson's syndrome.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Flavonoids; Male; Mice; Mice, Inbred C | 2007 |
Proteasome inhibitor does not enhance MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cysteine Proteinase Inhibitors; Disease Model | 2008 |
Pallidal burst activity during therapeutic deep brain stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Behavior, Animal; Deep Bra | 2008 |
PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Disease Models, Animal; | 2008 |
Striatal histone modifications in models of levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; Animals; Chromatin; Chromosome Aberration | 2008 |
Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2008 |
Preclinical models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Injections, Intra-Arterial; Injec | 2001 |
Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Analysis of Variance; Aniline Compo | 2008 |
Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Drug Combina | 1999 |
Differential regulation of striatal dopamine D(1) and D(2) receptors in acute and chronic parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Benzazepines; Chronic Disease; | 1999 |
D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Benzazepines; Dopamine Agen | 2000 |
Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Dopamine; Dopamine Agents; M | 2000 |
The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Ani | 1999 |
Ultrastructural changes in substantia nigra and striatum observed on a mouse model of Parkinson's disease induced by MPTP administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Male; Mice; Mice, Inbred Str | 1999 |
Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Binding Sites; Dopamine Agents; | 2000 |
Evidence for resistance to MPTP in C57BL/6 x BALB/c F1 hybrids as compared with their progenitor strains.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chimera; Dopamine Agents; Drug Resistance; Fe | 2000 |
Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Binding Sites; Carrier Prot | 2000 |
Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Callithrix | 1999 |
Excitotoxic ablation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Drug D | 2000 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced complex I inhibition is reversed by disulfide reductant, dithiothreitol in mouse brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Dithiothr | 2000 |
The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Disease M | 2000 |
The role of descending basal ganglia connections to the brain stem in parkinsonian akinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Brain Mapping; Brain Stem; Dom | 1998 |
In vivo PET studies of the dopamine D2 receptors in rhesus monkeys with long-term MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; F | 2000 |
Dopamine-receptor stimulation: biobehavioral and biochemical consequences.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease | 2000 |
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Antigens, CD; Dihydroxyphenylalanine; | 2000 |
Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Biological Clocks; Chloroc | 2000 |
MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Female; Genotype; Locomotion | 2000 |
Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Dopamine A | 2001 |
Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Brain; Disease Models, Anima | 2001 |
Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2001 |
Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Brain; Carotid Arteries | 2001 |
cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Gene Expres | 2000 |
Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; beta-Synuclein; Cell Line; C | 2001 |
Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 2001 |
Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Chloromethyl Ketones; Amino Acid Substituti | 2001 |
Neuroprotective aspects of a novel MAO-B inhibitor PF9601N.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2000 |
Parkin immunoreactivity in the brain of human and non-human primates: an immunohistochemical analysis in normal conditions and in Parkinsonian syndromes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Aged, 80 and over; Animals; Antibodies; B | 2001 |
Selective inhibition of MAO-B through chronic low-dose (R)-deprenyl treatment in C57BL/6 mice has no effect on basal neostriatal dopamine levels.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; M | 2001 |
Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Benzoates; Cocaine; Corpus Str | 2001 |
Strain-dependent susceptibility to MPTP and MPP(+)-induced parkinsonism is determined by glia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Death; Cell | 2001 |
Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dizocilpine | 2001 |
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caffeine; Cat | 2001 |
Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino | 2001 |
Differential regulation of striatal G protein levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration in C57 BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Down-Regulation; GTP-Binding | 2001 |
Neuroprotective effects of pramipexole in young and aged MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Antiparkinson Agents; Benzothiazoles; | 2001 |
Toxic effects of MPP(+) and MPTP in PC12 cells independent of reactive oxygen species formation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Differentia | 2001 |
Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Association Learning; Avoidance Learning; Con | 2001 |
Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Avoidance Learning; Caffeine; Central Nervous | 2001 |
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dose-Respon | 2001 |
Interactions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Anti-Arrhythmia | 2001 |
Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: potential contributors to spontaneous recovery from experimental Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cats; Corpus Striatum; Dopa | 2001 |
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Drug Ther | 2001 |
Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior | 2001 |
Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; D | 2001 |
Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Axons; Brain; Cell Death; Chro | 2001 |
Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Uptake Inhibitors; Animals; Behavior, Anima | 2001 |
Neuroprotective effect of riluzole in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dizocilpine M | 2001 |
Sequential up-regulation of the c-fos, c-jun and bax genes in the cortex, striatum and cerebellum induced by a single injection of a low dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Brain; | 2001 |
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Callithrix; Disease Models, Anim | 2001 |
Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamine | 2001 |
Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding, Competitive; Corpus Striatum; Diseas | 2001 |
Neuronal ectopic expression of tyrosine hydroxylase in the mouse striatum by combined administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 3-nitropropionic acid.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Convuls | 2001 |
Novel observations with FDOPA-PET imaging after early nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dihydroxyphenylalanine; Dise | 2001 |
Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Corpus Striatum; Dopamine Agoni | 2002 |
Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Cells, Cultured; Down-Regulation; | 2002 |
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Bacterial Agents; Astrocytes; Corpus Str | 2002 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine has a transient proliferative effect on PC12h cells and nerve growth factor additively promotes this effect: possible involvement of distinct mechanisms of activation of MAP kinase family proteins.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcysteine; Animals; Apoptosis; Brain; Cell Divisi | 2002 |
Significant reduction of 125 I-meta-iodobenzylguanidine accumulation directly caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine, a toxic agent for inducing experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3-Iodobenzylguanidine; Animals; Cells, Cultured; Desip | 2002 |
Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antineoplastic A | 2002 |
Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Caffeine; Dopamine; Dopamine A | 2002 |
Solid-phase synthesis of FKBP12 inhibitors: N-sulfonyl and N-carbamoylprolyl/pipecolyl amides.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbamates; Combinatorial Chemistry Technique | 2002 |
Method for culturing postnatal substantia nigra as an in vitro model of experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Cell Survival; Chimera; Coc | 2002 |
Calpain upregulation and neuron death in spinal cord of MPTP-induced parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calpain; Cell Death; Male; Mice; Mice, Inbred | 2002 |